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         INTRODUCTION
11. INTRODUCTION
According to WHO, Chronic Obstructive Pulmonary Disease is one of the
non communicable diseases included under the term “Chronic Respiratory
Diseases”. As per WHO, Non communicable diseases refer to “Diseases that are
chronic, life style related and usually progressive when not intervened” .This holds
true  for  COPD  also  as  it  is  chronic,  progressive  and  most  of  the  risk  factors  are
lifestyle related (smoking, biomass fuel exposure etc).  In India,  it  is  acknowledged
as a predominant health problem & requires management at primary care setting
itself. 1 It is predominantly a disease caused by smoking although other risk factors
may be responsible.
         A Working definition of COPD is given within the GOLD (Global initiative
for Chronic Obstructive Pulmonary Disease) Global strategy 2011 as (2)
“Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable
disease, is characterised by persistent airflow limitation that is usually progressive and
associated with an enhanced chronic inflammatory response in the airways and the lung to
noxious particles or gases”.
       Some patients develop significant airway limitation even without having
symptoms like chronic cough and sputum production.2 Hence, the abovesaid
definition did not include the symptoms aspect.
BURDEN OF COPD
COPD  is  a  leading  cause  of  morbidity  &  mortality  worldwide  and  also
causes social and economic burden on the patient and health care infrastructure,1
2which is increasing.3,4  Burden  of  COPD  is  cumulative  like  any  other  chronic
disease.
Mortality
According to the estimation of WHO, 64 million people had COPD and 3
million deaths occured in 2004 .According to Global burden of disease study, COPD
is  estimated  as  the  4th most common cause of death worldwide in 2008 and has
projected to become 3rd leading cause of death worldwide by 2020 3,4,5 and in
middle income countries by 2030.This increase is attributed to unceasing exposure
to risk factors and aging of the world’s population.4
Morbidity
It is a well known fact that DALY (Disability Adjusted Life Years) is one of the
ways for measuring morbidity. An estimation by Global burden of disease Study
reveals that COPD leads to 1.68 Year Lost due to Death / 1000 population
contributing for 1.8% of all Year Lost to Deaths (YLD).5  Also, COPD is expected
to become 5th leading cause of loss of DALY by 2020 worldwide, by 2030 in
middle income countries as per global burden of disease study.5  The morbidity data
is limited and this data says that as age increases, morbidity caused by COPD also
increases.6,7,8 It also gets feigned by co-morbid diseases like diabetes,
musculoskeletal disorder etc.9
Social burden
     By means of airway obstruction, COPD causes breathlessness during exertion
which slowly advances to severe disability and respiratory failure. Thus it limits the
3day to day activities of an individual, making him confined to bed, ultimately
leading loss of work.
Economic burden
COPD is associated with the significant economic burden. COPD
exacerbations account for the greatest proportion of economic burden on health care
system .In Europe, COPD accounts for 56% of total direct cost for respiratory
disease which is 6% of total health care budget.10  In united states, the estimated
direct costs of COPD are 29.5 billion dollars and indirect costs are 20.4 billion
dollars.11 In India, according to NCMH background papers by murthy etal, the
annual  treatment  costs  for  COPD  has  been  estimated  to  be  >Rs.  35000  crores  in
2011 and projected to be >Rs. 48000 crores in 2016.12
Prevalence of COPD
There are significant variations in prevalence data because of different
survey methods, diagnostic criteria and analytical methods.13,14   Different survey
methods are self report, physician diagnosed COPD,  only questionnaire, spirometry
etc.
Global prevalence
Earlier reports revealed higher prevalence rates for developed countries than
Asian countries. But the recent reports by Tan WC etal reveals a prevalence of 6.3%
combining 12-Asia Pacific countries which is almost two times higher than the
overall projected value of 3.8 % made by WHO for Asian countries.15 Recently,
4Burden of Obstructive Lung Disease (BOLD) has carried out surveys in several
parts of the world and estimated a prevalence of 3-11% among never smokers.8
Prevalence in India
As mentioned earlier, Indian studies on COPD too varied enormously in
regards to methodology, diagnostic criteria and results thus causing variation in
prevalence rates. SK Jindal et al from department of pulmonary medicine,
Chandigarh had reviewed all Indian studies on COPD in 2001.16  Out of 14 review
studies,  Only  two  studies  were  from  south  India.17,18  Prevalence  rates  in  most  of
these studies varied around 4-6% for males & 2-4% for females.
The Indian Council of Medical Research (ICMR) sponsored a study in India
on Epidemiology of Asthma and Chronic bronchitis in 2006 including 4 centres
namely Delhi, Chandigarh, Bangalore and Kanpur.19 This study reported a
prevalence rate of  5.0 % for males and 3.2 % for females > 35 years of age.  This
study was based on self reported questionnaire alone..
Risk Factors
COPD is a polygenic disease as it results from gene-environment interaction.
Like all other chronic diseases, COPD has modifiable & non-modifiable risk factors
that are preventable.2
Modifiable factors
Cigarette smoking is the commonest risk factor noticed globally. 20, 21   but
various epidemiological studies has got enough evidence that non smokers may also
5develop COPD.22, 23  This indicates the presence of other factors like environmental
tobacco smoke exposure, dust exposure at work place, outdoor air pollution &
indoor air pollution.24,25,26  Recent report says that exposure to biomass smoke
produced during heating & cooking biomass in poorly ventilated houses has become
an  important risk factor among women especially  in developing countries.27  Low
socioeconomic status was also found to be an another important risk factor in many
epidemiological studies.28
Thus COPD is preventable to a large extent if the risk factors are controlled.
Non-modifiable Factors
These are age, heredity, gender etc
Symptoms of COPD
COPD is characterised by chronic cough or sputum production, dyspnoea
that is persistent and progressive with history of exposure to risk factors.
  Burden of disease estimation is important for decision making, planning,
prioritising and allocating funds.16 This is specifically important for diseases that are
associated with preventable  factors like tobacco smoking. But, after exhaustive
review of literature, it was noted that there are not much data on prevalence of
COPD in south India,  especially in Tamilnadu .Hence the need of this study and it
had been undertaken in order to estimate the prevalence of COPD in Ellapuram
block of Thiruvallur District among adults aged 30 yrs and above and its relation to
various risk factors.
           OBJECTIVES
62.  OBJECTIVES
1) To estimate the prevalence of Chronic Obstructive Pulmonary Disease
among adults aged 30 years and above in Ellapuram Block of Thiruvallur
district, TamilNadu, 2012.
2) To study the associated risk factors & its prevalence.
        JUSTIFICATION
73. JUSTIFICATION
1) According to WHO, COPD is a major public health problem with increasing
prevalence especially in developing countries.
2) COPD is the leading cause of chronic morbidity and mortality worldwide 3,4
and it has projected to become 3rd leading cause of death worldwide  by
2020 3,4,5
3) Also,  COPD  is  expected  to  rise  to  5th  leading  cause  of  loss  of  DALY  by
2020, as per global burden of disease study.5
4) It also causes huge social and economic burden on the patient and health care
system .In India, the annual treatment costs for COPD has been estimated to
be >Rs. 35000 crores in 2011 and projected to be >Rs. 48000 crores in
2016.12
5) A disease with Such a huge burden is a preventable and treatable one
6) The disease has a long asymptomatic phase and by the time the patient
develops symptoms, 50% of their lung function capacity will be affected,
and much of the lung damage is irreparable.29
7) By early diagnosis and prompt intervention it is possible to relive symptoms,
prevent complications and reduce morbidity & mortality 30   thereby
improving the quality of life.
88) Moreover,  most of the risk factors are modifiable and stopping exposure to
these factors, even in the presence of significant airflow limitation, slows or
even halt the progression of disease. Some improvement in lung  function
may also occur 2
9)  Although several prevalence studies had been conducted in India, there are
only few population based studies and most of these were conducted two
decades back. After exhaustive review of literature, it has been found that the
recent  data  on  prevalence  of  COPD is  less  in  south  India,  especially  Tamil
Nadu.
            REVIEW OF
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94. REVIEW OF LITERATURE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4.1   HISTORY
        Chronic obstructive pulmonary disease (COPD) is a lung disease
characterized by airflow obstruction that interferes with normal breathing and
worsens over time. COPD is preventable, and can be treated and managed
effectively, when the disease is diagnosed early. Historically, the bronchitis
component which we today label as Chronic bronchitis (chronic cough and mucus
secretion) was first described by Badham in 1814.31 In 1821, Laënnec also described
the chronic bronchitis aspect, but in addition, he also portrayed the emphysema
component of the disease. An association between chronic bronchitis and
emphysema was discovered from post mortem studies into the morphology of the
airways and lung parenchyma.31
4.1.1 COPD TERMINOLOGY
          Diagnostic labels used for COPD, during the 1950´s and 1960´s were ‘chronic
bronchitis’, ‘chronic obstructive lung disease’ (COLD), ‘Chronic obstructive
respiratory disease’ (CORD) etc. In 1964, the term Chronic Obstructive Pulmonary
Disease (COPD), was first mentioned by Mitchell in USA. It is the well established
clinical term for obstructive lung function impairment most often due to chronic
bronchitis and/or emphysema. Emphysema is defined anatomically by airspace
enlargement due to disappearance of alveolar septae. Chronic bronchitis is
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characterized by chronic cough and sputum production that is present for > 3 months
in a year for the past 2 years. 2
4.1.2 DEFINITION OF COPD ACCORDING TO GUIDELINES
       The most well known guidelines were the American Thoracic society (ATS,
1995), the European Thoracic Society (ERS), and the British Thoracic Society (BTS,
1997). Some years later , the US National Heart, Lung and Blood Institute  (NHBLI)
together with World Health Organisation founded the Global Initiative for Chronic
Obstructive Lung Disease (GOLD). This is an international guideline for COPD
with the main aim to increase the awareness on COPD, and to decrease morbidity
and mortality of the disease. The first GOLD workshop result was presented in 2001
and there have been subsequent regular updates since then, with the most recent one
in December 2011.2 Most guidelines have also been updated since their inception.
The definition of COPD according to the latest GOLD guidelines 2 states that:
Chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease,
is characterized by persistent airflow limitation that is usually progressive and associated with
an enhanced chronic inflammatory response in the airways and the lungs to noxious particles
or gases.
4.1.3   COPD- An Undiagnosed Disease
Though there are published guidelines and standards for diagnosing COPD
including the recent GOLD guidelines, COPD remains an undiagnosed & untreated
disease due to the usage of multiple terminologies in definition, diagnostic
criteria etc. 32
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 4.2   PREVALENCE OF COPD
4.2.1 Global
         In  1990,  World  Health  Organisation  /  World  Bank   reported   COPD
prevalence as 9.33 per thousand individuals for males and 7.33 per thousand
individuals for females but the prevalence was found to be higher in developed
countries.19 Now,  globally,  the  prevalence  of  COPD is  approximately  10% in  the
general population. 7
In  a  review  article  by  Halbert  et  al.  in  2006, 13  the pooled prevalence of
COPD from 26 studies among adults aged  ?40 years was 9-10%.  The  most
common spirometric definitions used in that review were in accordance with the
GOLD.
A  multicentric  population based study on COPD done among rural women
in china in 2006,33 reported a prevalence of 5.4% .This study also found a significant
association of COPD with various factors like elderly, family history, low
educational level, smoking, exposure to occupational dusts etc.
A study done in rural south china by Shengming Liu,etal in 2007,34  reported
a overall prevalence of 9.4%. This study also highlighted a significant association of
COPD with biomass fuel exposure.
In Japan, the prevalence of 9.3% was reported in a primary-care setting study
conducted among 2250 patients aged more than 40 years.6
12
Prevalence of COPD was found to be 27% in a study done by Hanna
Sandelowsky etal in Sweden in 2006 among those with respiratory tract infections35.
They included patients of 40-75 yrs with respiratory tract infection and they found
that respiratory infection was not statistically associated with COPD.
In  a  Denmark  study,  done  in  2012  by  Løkke  A,  Ulrik  CS  etal,36 COPD
prevalence was reported to be 21.7%  among adults > 35 yrs . They also found that
number needed to screen to diagnose a new patient was 4.6
The results of a study from the northern part of Sweden by Lindberg A etal
in 2006 37 reported the prevalence of COPD according to the GOLD criteria as 57%
of  mild, 37% moderate, 5% severe, and 1% very severe forms of the disease.
 In the Spanish epidemiological study by Penna et al, 38   38.1 had mild, 39.7
moderate and 22% had severe forms of COPD according to ERS criteria.
4.2.2   INDIA
  There are several studies on COPD in India but published before 1990 and
there are only few population based studies in the past 10-15 years.18,39, 40, 41. Some
are hospital based studies, some done in special groups like workers 42,43 or patient
attendants. Only few studies had used standardized questionnaire and operational
definition of chronic bronchitis. These studies reported the prevalence ranging from
1.3-4.9 in females and 1.4-9.4 in males.
        Jindal et al in 2001,16 published a review article on burden of COPD from
population based Indian studies in adults of  ?30 years of age .There were 14
studies, of which only 11 were conducted in general population .The reported
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prevalence varied significantly in different population based studies .(Table 1)17,18,44,
39, 45-51 North  Indians  had  a  higher  prevalence  rate  of  2.12%  to  9.4%   for  males
compared to south Indians (1.4% to 4.08%). The prevalence rates for females also
varied between 1.33% to 4.9% for North and 2.55% to 2.7% for South. For
epidemiological purpose, the median prevalence rates were calculated as 5 % for
males  and  2.7  % for  females  aged   >30  years  of  age.  There  are  limitations  in  this
estimation because of differences in methodology, diagnostic criteria, data analysis
etc. For ex: Most of the studies were questionnaire based and few studies used Peak
Expiratory Flow in addition.
The biggest multicentric field study on COPD till date, in India, by SK Jindal
in 200619 (which was sponsored by the Indian Council of Medical Research (ICMR)
provides analytic data on prevalence and risk factors for COPD. Both rural and
urban areas were covered in the field survey using standardized questionnaire at four
large centres i.e., Bangalore, Chandigarh, Delhi. Approximately 35000 adults aged >
35 yr of age were surveyed and the estimated prevalence was 4.1% with 5.0 % for
men and 3.2 % for women. Prevalence rates varied significantly and the factors
responsible for this were tobacco smoking, exposures to biomass smoke and
environmental tobacco smoke.
A study by Sundeep Salvi etal52 reported a prevalence of 5.1%.This study
was done in 26 rural villages of  pune among 3600 study subjects of >25 yrs of age
using BOLD questionnaire and spirometry.
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4.2.3   Prevalence in Tamilnadu
Ray d et al 18   did a prospective epidemiological study of COPD from 1981-
1986 among the 9946 inhabitants of four villages of KV Kuppam block of north
Arcot district, Tamilnadu. They diagnosed COPD based on questionnaire followed
by peak flow meter only for the diagnosed persons to quantify airflow limitation.
They reported point prevalence of COPD as on 31st march 1986 as 12.5/1000.
A population based study among rural women of southern India--Tamilnadu
by Priscilla Johnson etal53 reported a prevalence of 2.44%. They included approx
900 women of more than 30 years age group and did spirometry.
Table 1 : Prevalence of COPD in various Indian studies (Taken from
http://www.indiachest.org/copd_guidelines/table1.html)
Study Population Year of study
prevalence (%)
Male female
Wig 46 Delhi Rural 1964 3.36 2.54
Sikand 45 Delhi 1966 7.0 4.3
Viswanathan 47 Patna 1966 2.12 1.33
Bhattacharya 48 U.P. Rural 1975 6.67 4.48
Radha 44 New Delhi 1977 8.1 4.6
Thiruvengadam17 Madras 1977 1.9 1.2
Viswanathan49 Delhi  Rural 1977 4.7 3.5
Delhi Urban 1977 8.0 4.3
Charan 50 Rural Punjab 1977 2.28 1.63
Malik 51 North India Rural 1986 9.4 4.9
Urban 3.7 1.6
Jindal 39 North India Rural 1993 6.2 3.9
Urban 4.2 1.6
Ray 18 South India 1995 4.08 2.55
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         The prevalence of COPD tends to be greater in older people, males and
people with high smoking habits 28,38,54
        An important factor influencing the available data regarding the prevalence
of COPD is the actual definition of COPD.55   The different definitions used in these
studies have led to difficulty in estimating the true prevalence. There is
heterogenecity of spirometric definitions, and the different spirometric criteria
invariably alter the prevalence of  COPD.56,57,58  Fixed FEV1/FVC (VC) ratio < 0.7
is generally accepted as the most important guide to identify airflow obstruction.
Given  that  FEV1/FVC ratios declines with age, a fixed ratio could result in an
increase in false positive diagnosis of COPD, resulting in a greater prevalence
associated with ageing. Moreover, to obtain data for the prevalence of COPD,
researchers have relied on either readings based on spirometric criteria, self-reported
respiratory symptoms via a questionnaire,  or a combination of the two. Prevalence
based on self-reported respiratory symptoms and physician diagnosis of COPD must
be regarded as the most imprecise due to the lack of both sensitivity and specificity.
For example, self-reported methods will include people with chronic bronchitis but
without airway limitation. Furthermore, the disease will not be diagnosed until
COPD patients have clinically obvious symptoms such as dyspnoea, but the fact is
that mild to moderately advanced COPD patients may not have any symptoms at all.
Hence, there exists the chance of missing them by self reported questionnaire.
4.3 ETIOLOGY OF COPD
          There are three hypotheses about the etiology of COPD, the British
hypothesis, the Dutch hypothesis, and the Fletcher hypothesis.
16
According to the British hypothesis, host and exogenous factors like repeated
chest infections, air pollution and smoking influence the pathogenesis for chronic
bronchitis. This in turn leads to hyper secretion of mucus which inhibits the host
defence, causing repeated acute or chronic respiratory tract infections and eventually
a decline in lung function.31
The Dutch hypothesis on the other hand, proposed that host genetic factors,
and environmental factors predict the hosts response to the exogenous factors.31
According to this theory, asthma, chronic bronchitis and emphysema are different
expressions of a primary abnormality in the airways, and an interaction between
genetic predispositions (atopy and bronchial hyper responsiveness) and exogenous
factors (smoking) determines which manifestation a subject develops. The reason
why subjects exposed to identical exogenous factors (tobacco smoke and
environmental pollution), developed different symptoms and manifestations i.e.
chronic bronchitis on its own, or in addition to airflow obstruction can be explained
by this concept of genetically determined host factors. According to this hypothesis,
asthma and COPD have a single genotype with two phenotypes.
Fletcher is probably the most well known researcher in this field from that
time. In 1970’s, he stated the Fletcher hypothesis, which resembles the Dutch
hypothesis.59-61  Fletcher revealed that in susceptible smokers (comparable with host
factors), tobacco smoking is strongly related to chronic bronchitis and airflow
obstruction, and that these were two different diseases. One of the two diseases was
chronic bronchitis without airflow obstruction and the other was airflow obstruction
which in some individuals could co-exist with chronic bronchitis. As part of normal
ageing process, in a healthy non smoker, from the age of 30–35 years, the FEV1
17
declines by 25-30 ml /year approximately but in a smoker, the decline gets doubled
to 50–60 ml per year as per Fletcher and Peto.59
Fletcher also showed that smoking cessation could halt this rapid decline.
It was demonstrated that different populations of smokers, i.e. susceptible and non-
susceptible smokers, showed different trends in their lung function decline.59-61   He
found male smokers to have a mean decline of about 50 ml/year and some with
rapid decline of about 90 ml/year, while smoking cessation returned the decline to a
non-smoking level.59
4.4   RISK FACTORS OF COPD
Risk factors for COPD can be divided into environmental and genetic host
factors with the disease arising from an interaction between the two factors.
Table: 2  Preventable risk factors associated with the development of COPD4
a) Smoking I.  Tobacco smoking
Cigrattee
Bidi
II. Environmental Tobacco
smoke
Maternal smoking
Passive Smoking
           b) Work exposure of Occupational dust
   c) Air Pollution
I. Indoor Pollution
II. Outdoor Pollution
           d) Diet
           e) socio economic status
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4.4.1   SMOKING
4.4.1.1. Tobacco Smoking
         The US Surgeon General reports states that cigarette smoking is the
predominant cause of COPD for both males and females. 20
Similarly  in  India,  it  has  been  found  in  a  study  by  SK  Jindal  et  al16   that
tobacco smoking was responsible for over 82% of COPD .Report on tobacco control
in India in 2004 by Reddy KS62 also mentioned the same findings.
 ‘Pack years’ is used to quantify the relationship between amount of cigarettes
and the duration of smoking .The formula 29 used to calculate pack-years is
          Number of cigarettes smoked per day
   _______________________________    x duration of smoking
                         20
For example, if a patient smoked 10 cigarettes for 30 years, the
 formula is     10
          20
According to a book written by Margaret Barnett on “COPD in primary
care” in 2006,29 a smoking history of 20 pack years is a significant factor
contributing to COPD.
Bidi is a famous smoking product of Indian cottage industry containing
crude tobacco in dried leaf of tendu tree and smoked as a cigarette. Yet other famous
method is to keep tobacco in a clay container and smoke either directly or indirectly
x 30 = 15 pack years
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by using long tube passing through a water container (i.e.,  ‘hukkah’)  –  This  is
common in older persons and in the Middle East.63
In an Indian study by Jindal SK et al in 2006 19, COPD was encountered in
smokers using these different tobacco products and the COPD prevalence among
bidi smokers were 8.2% and cigarette smokers were 5.9 % .This difference of higher
prevalence among bidi smokers than cigarette users was significant.
Almost  half  of  study  population-46.6%  of  smokers  were  found  to  have
COPD  in  a  study  done  in  semi  rural  area  of  Belgium  by  Vandevoorde  J,  et  al  in
2007.64
In a study by Tinkelman DG et al 65 done in USA, COPD prevalence among
smokers of > 40 years age was found to be 18.9%.
Bidi is more commonly used than cigarettes in India.62,66  A  study  by
Rahman M et al in 2000 on Bidi smoking and health reported that though the
amount of tobacco used in bidi is ¼ th of cigarette, it is equivalent to cigarette
smoking as higher puff frequency is essential to keep bidi alight that of cigarette.
Hence it is more likely associated with functional impairment of lungs than cigarette
smoking.
Chhabra SK et al 67   did a study on patterns of smoking in Delhi in 2001 and
found that bidi smoking of > 2.5 pack years was associated with respiratory
symptoms and airflow limitation than cigarette smoking.
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Smoking cessation
Abstaining from smoking is the most effective strategy in halting the
progression of COPD and Studies had revealed that this has a beneficial effect on
cough, sputum and FEV1. This was also observed in a randomised study by Kanner
RE etal68 in which smoking cessation intervention group had significant
improvement in symptoms.
As already mentioned, Fletcher and Peto59 observed that decline in FEV1
decreased after quitting smoking. This finding was also supported by Lung Health
Study69 which revealed a slight improvement in FEV1 during the first 2 years after
quitting smoking followed by a lesser decline in FEV1 thereafter. But continuous
decline occurs in smokers who smoke continuously. The above findings mark the
importance of smoking cessation .
4.4.1.2. Environmental tobacco smoke
According to Dayal HH etal,70  Passive  smoking  to  cigarette  or  bidi  has  also
contributed to the development of COPD as they increase the lung burden of inhaled
gases.
        Passive smoking from male smokers inside the home is a predominant risk
factor for COPD in non smoker females.26
       Those Exposed to environmental tobacco smoke had an odds of 1.4 for
developing  COPD  than  others.  This  important  observation  was  made  in  a
multicentric study by Jindal et al in India. 19
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4.4.2   Outdoor air pollution
            Studies  from  west  by  Sunyer  J  in  200171 had found significant association
between COPD and air pollution.
             Though there  are  evidences  that  air  pollution  aggravates  COPD,  its  role  is
minimal when compared to cigarette smoking (Bourke, 2003). Outdoor air
pollutants are heavy particulate matter, carbondioxide, sulphur dioxide and nitrogen
dioxide (released by the burning of coal and petroleum fossil fuels) and ozone . Air
pollution has worsened now-a days due to traffic congestion (vehicle exhaust), poor
housing,  sanitation, garbage accumulation etc.
4.4.3. Indoor air pollution
          The highest concentration of indoor air pollutants are due to burning of
biofuels or biomass fuels. They refer to any plant or animal based material burnt by
humans such as wood, dung cake, agricultural crops etc.
                           Fig: 1 The Energy Ladder ( smith et al 1994)
22
The above figure shows the step ladder pattern of the type of cooking fuel.
As the ladder goes up, cleanliness and cost of fuel also increases.
Globally, approximately 3 billion people are using biomass  as their fuel for
cooking and heating2 and these are also widely used by rural households in India. It
has been estimated that 75% of rural India use this fuel for cooking.72
According to GOLD guidelines 2011, cooking wood, cowdung or coal  in
open air or using poorly functioning stoves has led to highest ever measured level of
air pollution2.
Exposure to this biomass smoke became a predominant risk factor especially
for women in rural of developing countries who face more burden.73
Biomass combustion releases carbon monoxide, nitrogen dioxide, sulphur
dioxide, formaldehyde, carcinogens such as benzene, benz(o)pyrene etc. which play
a important role in etiopathogenesis of COPD according to a study by Balakrishnan
K etal.74
In a study by Priscilla Johnson et al among Tamilnadu rural women,53
prevalence was high among biomass fuel users than clean fuel users with an odds of
2.5 Vs 2.0 though statistical association was not obtained.
Depending on the social and economic background, type of fuel used in
India varies. The other type of fuel used in India are LPG and Kerosene stove. Toxic
respiratory irritants are produced by kerosene stoves. With regards to LPG, butane
gas is free of any respiratory effect, methane added in LPG to detect leakage is also
in  smaller  quantities  only  and  CO  that  is  released  during  burning  of  LPG  is  also
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quickly converted to carbon di oxide..75   On  the  whole,  LPG  pose  a  very  little
respiratory problem in a well ventilated house.
Other causes for indoor air pollution are passive smoking, smoke from  near
by houses, pollutants from furniture, building material, biological organisms etc.
4.4.3.1   Impact of improved cooking stoves on indoor air pollution
                            Fig :2  Improved cook stove (Sukhad stove)
It is a double hole stove with chimney. stronger heat is produced under both
the holes thereby reducing the cooking time. A study by Chaya Chengappa etal 76 on
the impact of improved cook stoves one year after installation in Bundelkhand
region of central India has showed significant decline in indoor pollutants such as
CO, SO2 etc.,
4.4.4. Occupational exposure
Occupational exposure to organic and inorganic dusts, chemicals, fumes are
under appreciated risk factor for COPD as observed in studies by Trupin L et al in
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200377 and Matheon MC et al in 2005.78 But When the exposure is intense or
prolonged, they can cause COPD independently apart from factors like cigarette
smoking.4
Table: 3 Occupational risk factors for COPD
Agents with Good evidence are
Cadmium
Silica
Jobs with higher risk of COPD
Coal miners
Construction or Cement workers
Furnace / metal workers
Transport
Wood / Paper
Cotton
General Population
Exposure to Dust/ fumes
            Source : G. Viegi Epidemilogy of COPD Respiration 2001, 68:4-19
4.4.5 GENETIC FACTORS
         As  already  stated,  COPD  occurs  as  a  result  of  genetic  &  environmental
interaction. This has been proven by the fact that all smokers does not develop
significant COPD.
A study by Lundback et al in 200354 found that 15-50% of smokers only
developed COPD i.e. genetic susceptibility of the individual to the environmental
exposures play an important role.
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Moreover, familial risk of airway obstruction was seen in the siblings of
severe COPD patients in a study by McCloskey et al in 2001.79
4.4.6   Other factors:
4.4.6.1   Diet
     Surya Kant etal80 in  his  study,  found  that  increased  intake  of  salt  and
decreased intake of fruits and vegetables have also contributed for COPD mortality
and morbidity.
4.4.6.2   Socioeconomic status:
  In an epidemiological study of COPD by Viegi G etal,28 it is strongly evident
that low socioeconomic status is a risk factor for COPD and it has been proved in
few other studies also . This may be attributed to the presence of factors like
overcrowding, use of biomass fuel, poor nutrition, infections etc.
4.4.6.3   Age & Gender:
Many  studies  from  developed  countries  has  shown  that  COPD  is  almost
equal in both the sexes which may be due to prevalence of smoking among women
now-a-days.11
Many population based studies, for example: study done by Nanshan Zhong
et al in china-2007,81 Danielsson P, et al in Sweden during 2011,82  Jindal SK et al
in India  2006 19 has proven that COPD is significantly associated with advancing
age.
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4.4.6.4   Tuberculosis:
A  cross  sectional  population  based  study  done  by  Danielsson  P,  et  al 82 in
Sweden has found significant association between COPD and previous tuberculosis
( p value of 0.08).
4.5   Pathology & Pathogenesis
          COPD is characterised by inflammatory and structural changes in airways,
lung parenchyma and pulmonary vasculature. Factors involved in pathogenesis
include oxidative stress, Protease-Antiprotease imbalance, inflammatory mediators
like cytotoxic T cells, neutophils & macrophages.
4.5.1   Pathophysiology
        It includes mucus hypersecretion, obstruction of small airways due to
inflammation, fibrosis & mucus hypersecretion leading to decrease in FEV1, PEFR,
gas-exchange abnormalities, Pulmonary hypertension due to hypoxic
vasoconstriction etc.2
4.6   Symptoms
 Disease begins with an asymptomatic phase and the symptoms phase starts
only after a decline in lung volume to 50% of the predicted values.29
       COPD is characterised by chronic cough, chronic sputum production &
progressive and persistent dyspnoea.
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4.7   Diagnosis:
          According to GOLD guidelines (December 2011 Update) 2 the presence of any
of  the  following  symptoms  in  an  individual  over  40  years  of  age  should  clinch  a
clinical diagnosis of COPD followed by spirometry for confirmation.
       a)  Dyspnoea  that  is  persistent,  progressively  worsens  over  time  and  is
characteristically worse after exercise;
       b) Chronic cough
       c) Chronic sputum production;
        d) History of exposure to risk factors such as tobacco smoke, smoke from
biomass  fuel or occupational dusts and chemicals and/or
       e) Family history of COPD
Usually COPD patients will have only small amount of sputum after
coughing bouts. Large volume of sputum production suggests bronchiectasis and
purulent sputum reflects bacterial exacerbation.2
4.7.1   PHYSICAL EXAMINATION
Physical signs of airway obstruction are rare to see till significant
impairment in lung function has occurred. Physical findings of hyperinflated lungs
such as low-lying diaphragms, decreased breath sounds, obliteration of cardiac
dullness and hyperresonant chest percussion are highly specific for COPD, but
usually found only in advanced disease.
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Badgett RG etal,83 in his study, revealed that it is a crude and insensitive
means of detecting airway obstruction and is only rarely diagnostic in COPD.
4.7.2    Spirometry
As per GOLD guidelines updated 2011,2 spirometry is the gold standard for
confirming and staging COPD. It can be used not only for the diagnosis but also for
classification of its severity, and progression of the disease.
4.7.3     RADIOLOGY
4.7.3.1   CHEST XRAY
Postero-anterior and lateral chest films may be entirely normal in mild
disease. As COPD advances, abnormalities reflect emphysema, hyperinflation, and
pulmonary hypertension..
4.7.3.2   OTHER TESTS
         CT scan, lung volume measurements by plethysmography, helium dilution,
nitrogen washout, or single-breath methods typically show hyperinflation (elevated
TLC) and air trapping (elevated residual volume [RV]), and thus are useful to
exclude restrictive lung diseases. The carbon monoxide diffusing capacity (DLCO)
is an indicator of emphysema and is roughly inversely correlated with the anatomic
extent of emphysema in patients who have an FEV1 greater than 1.0 L.
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4.7.4   Risk assessment
       According to GOLD guidelines 2011, before starting treatment, patient’s risk
should be assessed based on severity of symptoms measured by COPD Assessment
Test(CAT), grading of disease severity by lung function test and risk of
exacerbations (table:4)
                             Table : 4    Risk assessment
Source: GOLD guidelines updated 2011,pg: 43
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4.8   Complications of COPD
? Bronchiectasis
? Lung carcinoma
? Pneumothorax
? Pulmonary embolism
? Cor pulmonale
4.9   Treatment:
According to GOLD guidelines updated 2011, Once COPD is diagnosed, it
should be managed effectively with individual assessment of the disease to reduce
symptoms and future risks.
Table: 5   Treatment goals
Source: GOLD guidelines updated 2011,pg 42
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According to Gold guidelines updated 20112,  following  are  the  key
points in treating COPD patients
1. Smokers should be adviced smoking cessation as it is the most effective
intervention to halt the progression of the disease.
2. Appropriate pharmacological therapy will relieve symptoms, reduce the
frequency & severity of exacerbations thereby improving the exercise
tolerance and quality of life.
3. Each pharmacological treatment should be patient specific & guided by
severity of symptoms, grading, risk of exacerbations, etc.
4. Influenza & pneumococcal vaccine administration as it benefits especially
elderly and severe patients.
5. All patients who are dyspnoeic while walking on level ground on own pace
should be offered pulmonary rehabilitation.
4.9.1 Pharmacological treatment For COPD symptoms
       There exists Evidence A for the use of bronchodilators either on regular basis
or as-needed basis in reducing or preventing COPD symptoms.
Table 6 represents the doses of bronchodilators used in the treatment namely
Beta 2 agonists, anticholinergics, combined therapy etc.
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                     Table : 6   Doses of various bronchodilators
Drug
Inhaler
(microgram)
Duration
of action
Level of
evidence in
improving
symptoms &
lung volumes
Beta 2 agonists
Short acting Evidence B
Salbutamol 100, 200 (MDI& DPI) 4-6 hrs
Terbutaline 400,500 (DPI) 4-6hrs
Fenoterol 100,200 (MDI) 4-6hrs
Long Acting
Salmeterol 25-50 (MDI &DPI) 12hrs Evidence A
Formoterol 4.5-12 (MDI &DPI) 12hrs Evidence A
Indacaterol 75-300 (DPI) 24hrs Evidence A
Anticholinergics
Short acting
Ipratropium bromide 20,40 (MDI) 6-8 hrs
Oxitropium bromide 100 (MDI) 7-9 hrs
Long Acting
Tiotropium bromide 18 (DPI) 24 hrs Evidence A
Combinationofbeta2agonis Andanticholinergic
Salbutamol/Ipratropium 75/15 (MDI) 6-8hrs
Corticosteroids
Budesonide 100,200,400
(DPI)
Beclomethasone 50-400 (MDI &DPI)
Source: GOLD guidelines updated 2011
MDI-Metered Dose Inhaler              DPI-Dried Powder Inhalers
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4.9.1.1   Other drugs:
This includes 1. Methyl xanthenes—Theophyline (SR),100-600mg pill
                      2. Phosphodiesterase-4 inhibitor—Roflumilast, 500mcg pill
 once daily.
According to a randomized controlled trial by Calverley PM etal in 2009,84
Roflumilast is more effective in improving lung function when combined with long
acting bronchodilators. It acts by inhibiting the cyclic-AMP thereby reducing
inflammation. It has no direct bronchodilator activity.
4.9.1.2   Combination bronchodilator therapy
The results of a study by Vogelmeier etal in 200885  says that Combination of
bronchodilators with varied mode and duration of action increases the degree of
bronchodilation with few side effects.
In a study by COMBIVENT inhalation solution study group 86, there exists
evidence  B  for  the  finding  that  combining  short  acting  beta2  agonists  and
anticholinergic is more effective in improving symptoms and lung volumes than
either drug alone.
Table 7 represents the pharmacological treatment according to patient’s
group.  Patients  are  classified  into  four  groups  A,B,C&D  based  on  their  risk
assessment explained earlier in table 4.
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    Table: 7   Initial pharmacological treatment according to patient’s group
Patient
group
1st choice 2nd choice Alternative choice
A
Short acting
Anticholinergic /
beta 2 agonist
Long acting
Anticholinergic / beta 2
agonist
Theophyline
B
Long acting
Anticholinergic /
beta 2 agonist
Long acting
Anticholinergic and
beta 2 agonist
Short acting beta 2
agonist /
anticholinergic or
theophyline
C
Inhaled
corticosteroid plus
long acting beta 2
agonist or
anticholinergic
Long acting
Anticholinergic and
beta 2 agonist.
Short acting beta 2
agonist and/or short
lived anticholinergic
or theophyline
D
Inhaled
corticosteroid plus
long acting beta 2
agonist or
anticholinergic
Various combinations
with inhaled steroids
Short acting beta 2
agonist and/or short
acting
anticholinergic or
theophyline
Source: GOLD guidelines updated 2011, pg 46
4.9.2   Pharmacological treatment for smoking cessation
According to a randomized controlled trial by TakshinDP etal, Varenicline87
and bupropion88 have been found to have long term quit rates.
4.9.3      Non pharmacological treatment: It includes
 4.9.3.1   Nicotine replacement therapy for smoking cessation
This includes nicotine gum, inhaler, nasal spray, patch etc.
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4.9.3.2   Five step smoking intervention program
According to guidelines by American Medical Association 89 and cancer
institute  manual  for  physicians  by  Glynn  TJ  etal,90 there  are  five  step  for
smoking intervention.
                                 Table: 8  Smoking intervention
1. ASK
Ensure that, for every patient at every clinic visit, tobacco-use
status is questioned and documented.
2. ADVICE
 Motivate all tobacco users to stop smoking in a clear, strong
manner.
3. ASSESS
Ask every tobacco user whether they are willing to make a
quit attempt at this time (e.g., within the next 30 days)
4. ASSIST
Help them in smoking cessation, provide counseling; intra-
treatment social support etc., Recommend the usage of
approved pharmacotherapy except in special situations.
5. ARRANGE  Schedule follow-up contact, either in person / telephone.
4.9.3.3   Vaccines
 According to the recommendations of advisory committee on immunization
practices  by  Centre  for  Disease  Control  (CDC)  in  2009,  influenza  vaccine reduces
severity and death.91.Vaccine must be given one time a year.
Pneumococcal vaccine is advised for  patients older than 65 yrs or younger
patients with co-morbid conditions as per the report by Centre for Disease Control
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titled “recommended adult immunization schedule”, 2010 92  and a study by Jackson
LA etal.93
4.   Oxygen therapy & ventilator support for those with chronic respiratory failure.
5. Pulmonary rehabilitation
The components of pulmonary rehabilitation includes smoking cessation,
exercise training, nutrition counselling and education. The aim is to decrease
symptoms & improve quality of life. The minimum duration should be 6 weeks.2
          Table :9   Advantages of Pulmonary Rehabilitation in COPD
1. Increases exercise capacity .
2. Decreases the perceived intensity of dyspnoea.
3. Improves quality of life.
4. Decreases the number of hospital admissions and days in the hospital .
5. Decreases anxiety as well as depression associated with COPD .
6. Improves survival .
7. Improves recovery after hospitalization for an exacerbation .
8. Increases the effect of long-acting bronchodilators .
   Source : GOLD guidelines updated2011,pg 36
Table 10 below explains the overall non pharmacological treatment according to
patient’s group.
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                Table : 10  Non-Pharmacological treatment of COPD
Patient
group
Essential Recommended
Depends on local
guideline
A Smoking cessation
Physical
activity
Flu &pnumococcal
vaccine
B-D
Smoking cessation
Pulmonary
rehabilitation
Physical
activity
Flu &pnumococcal
vaccine
   Source: GOLD guidelines updated 2011, pg 44
4.9.4.   Surgical treatment 2
1. Lung volume reduction surgery for reducing hyperinflation
2.   Bullectomy for emphysematous bullae
3.   Lung transplantation
4.9.5   Monitoring & Follow up
      According to GOLD guidelines updated 2011, monitoring and follow up of
COPD patients for symptoms, smoking status, lung function, exacerbations, co-
morbidities etc is very essential .
           MATERIALS
                AND
            METHODS
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5. MATERIALS AND METHODS
5.1   Study Design:
Community based cross sectional study
5.2     Study Area :
           In Ellapuram  block of Thiruvallur district, TamilNadu.
5.3     Study period:
           August to October 2012.
5.4     Study Duration:
December 2011 to December 2012
5.5     Study population:
5.5.1   Inclusion criteria:
Both males & females aged 30 yrs and above
5.5.2   Exclusion criteria:
? Those not willing to participate
? Pregnant women
? Those with sputum positive pulmonary tuberculosis
? Those who are unable to understand and perform lung function test
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? Persons with heart disease as assessed by history/records
? Those having any acute illness.
5.6    SAMPLE SIZE
Calculated Sample size   :  470
Sample size covered       :   480
5.6.1   SAMPLE SIZE CALCULATION:
      Formula for cluster sampling method:
  x design effect
     Where,
Z alpha=1.96 at 95% confidence interval
    P=Prevalence
    Q=1-P
    L=Allowable error
5.6.1.1   Calculation of design effect
Design effect=1+{ cluster size-1} x Rate of homogenecity
Cluster size of 20 was taken for this study as it  is  possible to see atleast  10
study subjects per day thus making 2 days visit for each cluster.
Rate of homogenicity = 0.02 {proportion of disease in general}
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Therefore, design effect = 1+{20-1] x 0.02
                                     =1+0.38
                                     =1.38
Prevalence {P}= 22% based on pilot study. Though there are studies on
COPD in India using peak flow meter,17,18,39,44  all  were done in the past  and there
are no recent studies. Hence pilot study was done and its prevalence was taken for
sample  size  calculation  of  this  study.  Study  population  of  the  pilot  study  were
excluded from the main study.
Q =1-22=78
L {allowable error of 20% of prevalence was taken for this study i.e. 20%
of  22 = 4.4}.
Substituting all the above values in the formula,
                 =   x design effect
                 =   x 1.38
                =   x 1.38
               =  469.89
                =  470
Calculated Sample size = 470
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5.7    Sampling method:
   Cluster sampling method.
5.7.1   Method of choosing clusters
1) With the cluster size of 20, number of clusters needed = sample size /
cluster size = 470/20 = 23.5= 24 clusters. Therefore, with equal cluster
size of 20, sample size to be covered for 24 clusters was calculated as
24x20 = 480
2) Ellapuram block has 53 panchayat villages. The population of 53
panchayat villages varies from a minimum of 775 to a maximum of
7120 (Annexure VI)
3)  Cumulative population of the villages were calculated.
4) Cluster interval = cumulative population / total number of required
                                                                                           clusters
                              = 1,14,689 / 24
                             = 4778.7
                             = 4779
5) The cumulative population of a village, where the cluster interval (4779)
fell  was taken as the1st cluster and subsequent clusters were selected by
adding cluster interval to the previous number and so on till the required
number of clusters were obtained.
5.8    Measuring Tools:
 1) Semi structured Questionnaire
 2) Peak expiratory flow meter to measure airflow obstruction
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1) Questionnaire for the present study was developed based on
BOLD(Burden of Obstructive Lung Disease) questionnaire, GOLD guidelines
updated 20112 and International primary Airways Group( IPAG-2005)-A guide for
primary care  physicians.94   IPAG questionnaire  which  was  used  in  this  study  for
COPD scoring has identified questions in peer-reviewed literature as having more
diagnostic value and has a sensitivity of 91% and specificity of  49% in diagnosing
COPD according to a study by Sichletidis et al.95 IPAG questionnaire has
considered a score of  ?17 as a favourable score. Questionnaire was modified
according to the local culture and validated with the help of expert & pilot study
(Annexure III). It was translated into Tamil and back translated to English.
    Questionnaire of the present study was divided into 6 parts namely
a)  Socio demographic details
b)  History regarding exposure to potential risk factors
c)  History regarding respiratory symptoms
d)  History to rule out Asthma
e)  COPD scoring for smokers using IPAG questionnaire
f) measurement findings
2) Peak expiratory flow meter :
a) It is used to measure Peak Expiratory Flow Rate (PEFR) which is defined
as the highest flow achieved from a maximum expiration (obtained from
hard & fast blow) after maximum inspiration.96
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b) In  this  study,  Peak  Expiratory  Flow  (PEF)  was  measured  using  pocket
Peak-- mechanical peak flow meter which is ATS/EU complaint. (ATS-
American Thoracic Society & EU-European)(Fig shown in annexure IX)
c) Validity of this instrument is +/- 10% satisfying the ATS/ERS Task force
recommendations.96
d) Reliability of the instrument was tested daily against another peak flow
meter and the same instrument was used throughout the study.
5.9    Data collection method
a)  Data collection was done in the study area after obtaining permission
from The Director of Institute of Community Medicine, Madras Medical
College, The Dean of Madras Medical College and the Institute Ethics
Committee (Annexure X).
b) Data was collected by house to house visit in the study area. In each
selected village, a starting point was selected randomly and using right
hand rule, adjacent houses were recruited continuously till 20 households
were reached as the cluster size was 20. Where the house was locked, the
next house was taken for the study. In each household, only one eligible
person was selected for the study by simple random technique (lottery
method).
c)  After a brief introduction and obtaining their informed consent, relevant
information was obtained from the respondent using the semi structured
questionnaire in the local language.
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d)  Questionnaire was read out to the study subjects in the same order as
listed in the questionnaire .
e)  If  the  study  subject  did  not  understand  the  question,  it  was  repeated  in
the same manner without probing for the answer.
f) Each study subject was then subjected to pulmonary function test (PEFR
– Peak Expiratory Flow Rate) after measuring their height and weight.
5.9.1   Measurement of PEFR (Peak Expiratory Flow Rate)
PEFR measurement was done after undergoing basic hands on training in
pulmonary function test at National Institute for Research in Tuberculosis, chetpet,
Chennai.  PEFR  was  measured  following  ATS/ERS  Task  force  guidelines.96 in
litres/minute.
a) After giving prior instructions, technique was demonstrated separately to
each individual.
b) Following demonstration, subjects were asked to make trial attempts to
detect faults.
c)  Once the study subject had gained confidence, the test was performed in
the  sitting  position  & he/she  was  asked  to  inspire  maximally  and  blow
out without any hesitation as fast and as hard as possible into the meter.
d) It was taken care that mouth was sealed tightly around the mouth piece
of the peak flow meter during the procedure.
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e) The test was repeated for 3 times for every individual & best of three
attempts was taken for data analysis.
f) Disposable mouth piece was used for each individual.
Both within manoeuvre and between manoeuvre evaluation of the PEFR
performance of each individual was done as per ATS/ERS guidelines.
Within Manoeuvre evaluation
For this evaluation, it was ensured that while blowing, there was good seal at
the mouth and no hesitation in the start.
Between Manoeuvre evaluation:
For this evaluation, the 3 PEFR measurements of each individual was
compared at the end and if the largest two out of three acceptable blows are not
reproducible within 40 litres/minute, two additional blows were performed. This is
done to detect manoeuvre induced bronchospasm.
5.10    Interpretation of PEFR
a) Since  PEFR  is  influenced  mainly  by  sex,  age  &  height  of  the
individual,97 for interpretation, each observed value requires comparison
with the reference values (also known as predicted values) for that
particular age, height and sex. Predicted values can be estimated from the
normal subjects of same anthropometric measurements97
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b) Predicted values for this study was obtained from a study by Rajendra
prasad et al98 titled “Prediction model for PEFR for Indian population”.
This prediction model is based on age, sex & height of the individual.
Formula for predicted values are as follows,
                     For males:      -2.294 x age + 3.38 x Height in cms
                     For females:   -2.8 x age + 3.05 x Height in cms
c) Then, observed value (best of three measurements) of each person was
compared with the corresponding predictive value of that person for
interpretation.
d) COPD was diagnosed as per the diagnostic criteria discussed later.
Although spirometry is the gold standard test for diagnosing COPD,2   it was
not used in this study  because of the following practical issues in its usage in
primary care setting (2,99,100)
a)  It is costly and also not widely available
b) Involves complex procedure and consumes more time.
c)  Calibration on a regular basis is needed for spirometry.
d)  Investigator needs training in performing spirometry effectively.
e)  Maximal patient effort is needed in performing the test .
f)  Many studies have questioned its benefits in primary care setting
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Hence, peak expiratory flow meter was used in this study which is
a) inexpensive
b) easily available
c) simple procedure that may be carried out in the field
d) requires only short expiration time in contrast to spirometry
e) easy to interpret .
Moreover , GOLD guidelines updated 20112 and many other studies support
the use of PEFR in primary care setting where spirometry is not feasible.101,102,103
For example, a study by Jackson H et al  in 2003,101 made an important note
that   PEF ,when  used  as  a  screening  method  for  COPD in  primary  care,  will  save
money for interventions like  smoking cessation rather than spending resources on
spirometric tests. According to the same authors, 101 the  peak  expiratory  flow rate
( PEFR ) cut-off value of  < 80%  of  the predicted, has the sensitivity of 91% and
specificity of 82% in diagnosing COPD and hence may prove to be a valuable tool
in diagnosing COPD. Llewellin et al,103 in  his  study,  states  that  a  normal  peak
expiratory flow may rule out clinically significant COPD in adults”.
5.11   Other measurements used in this study
Each study subject’s height & weight was measured for calculation of
reference values for PEFR and Body Mass Index.
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5.11.1    Height
It was measured using portable plastic staturemeter (Bioplus TM) which is a
wall mountable type of stadiometer & has measurements upto 200cm and the same
instrument was used throughout the study. During field survey, double sided glue
tape  (removable)  was  pasted  on  the  back  of  the  meter  to  fix  it  on  the  wall  at  a
distance of 2meter from the floor. The study subject was then asked to stand against
the  wall  without  footwear,  with  feet  together,  standing  as  tall  as  possible  with  the
eyes level and looking straight ahead Then end of the instrument was lowered to the
level of head to measure height.
5.11.2   Weight
It  was  measured  using  a  portable  weighing  machine  (Bellita  R).  The  scale
was zeroed before weighing each person. Then the study subject was asked to stand
on it without any footwear and looking forward. The same machine was used
throughout the study & calibrated before each visit using standard known weights.
5.12    Services rendered:
Those who were diagnosed to have COPD were referred to the
pulmonologist in near by Government hospital. Bronchodilators like deriphyline and
salbutamol were prescribed for the persons having dyspnoea and they were also
motivated to utilise the yoga services already available in nearby Government health
facility. Health education regarding cessation/reduction of risk factors  were given to
the study population. For ex: smokers were given health education regarding adverse
effects of smoking using posters and motivated to quit smoking. Those who were
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using biomass fuel for cooking were adviced to change to cleaner fuels like LPG if
affordable. Non affordable persons were adviced to improve the combustion
efficiency by drying wood before using, using lid for cooking vessel while cooking
etc. so that cooking period and exposure time will be reduced. Overall, all of them
were adviced to improve ventilation in the kitchen wherever possible and to use
chimneys. Apart from this, list of smokers in the study population were given to the
corresponding local health worker for the purpose of reinforcing cessation of
smoking.
5.13      Operational definitions
5.13.1   Operational definition of COPD
A study subject was diagnosed to have COPD when the observed peak
expiratory flow rate is < 80% of the corresponding predicted value. This cut-off
point is having a sensitivity of 91% & specificity of 82% 101 in diagnosing COPD
i.e. it will detect more than 90% of  persons with COPD in the community including
all moderate and severe diseases.
5.13.2    Body Mass Index:
 It was calculated as                weight in kg
  height in m2
5.13.3     Smoker
          A smoker was defined by the history of regular smoking of either cigarette,
bidi or hookah, for 1 year or more.
50
5.13.4    Current smoker
A smoker who continued to smoke till one month prior to the date of survey.
5.13.5    Ex-Smoker
A smoker who stopped smoking for more than a month and continued
cessation till the date of survey.
5.13.6    Non-Smoker:
  Who has never smoked or smoked less than a year.
5.13.7    Passive smoking
             A study subject was considered as passive smoker when one or more family
member used to smoke in his /her presence.
5.13.8    Exposure to cooking fuel combustion
             It was established by the history of regular cooking at home by the study
subject.
5.13.9    Adequate ventilation
             It is defined as the presence of cross ventilation or chimney or both
5.13.10    Chronic cough
 It is defined as the presence of “cough on most of the days for atleast 3
months in a year for two consecutive years” 2
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5.13.11   Chronic sputum
   It  is  defined as the presence of “sputum on most of the days for atleast  3
months in a year for two consecutive years” 2
5.13.12   Dyspnoea Scale
  Scale of British Medical Research Council was used to determine the
degree of dyspnoea.
5.14      Data Entry
 Data Entry was done in an Excel Sheet.
5.15     Data Analysis
It was carried out using SPSS Software version 16.0
The significance value established in all the analysis was P-Value < 0.05.
Chi square test was performed to determine the association between
qualitative variables.
               RESULTS
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6.   RESULTS
This cross sectional study included 480 participants from 23 Panchayat
villages in Ellapuram block of  Thiruvallur district, Tamilnadu. The study estimated
the prevalence of Chronic obstructive pulmonary disease among the participants and
also the risk factors for the disease.
6.1   Socio demographic details of the study population
Among the 480 adults who took part in this study, majority of them belonged
to the age group of 30-39 yrs (31.9%) followed by 30% in 40-49 years age, 24.3% in
50-59 years and 13.8% above 60 years (Fig:3) Females were predominant in the
study with 64.8% compared to males(35.2%)(Fig:1).It was also seen that among the
study participants, 94.4% were Hindus, 3.1% Christians and 2.5% Muslims (Fig: 4)
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94.40%
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Fig: 4   Religion wise distribution
Hindu
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6.1.1   Education
Table: 11 shows that majority of the study participants were illiterates
(36.9%) .Among the literates, those who completed 6th-12th std were the highest with
31.2% followed by primary education (27.1%) and degree/others (4.8%).
            Table: 11   Education wise distribution of the study population
Education No. Percentage
Illiterate 177 36.9
1-5th 130 27.1
6-12th 150 31.2
Degree/ others 23 4.8
Total 480 100
6.1.2    Socio economic Status
The percapita income was calculated from the total family income mentioned
by the participants and socioeconomic classification was done based on Modified
BG Prasad scale (Annexure IV). From table:12, it has been observed that 6.7%
belonged  to  class  I,  10.8%  in  class  II,  33.3%  in  class  III,  35.4%  in  class  IV  and
13.8% in class V .
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Table: 12 Socio economic Distribution of study population
Percapita income SES No. Percentage
? 3259 Class I 32 6.7%
1630 -3258 Class II 52 10.8%
978 – 1629 Class III 160 33.3%
489 – 977 Class IV 170 35.4%
<489 Class V 66 13.8%
Total 480 100%
6.1.3   Occupation
Fig:5 shows that majority of the study population were coolies
(54.4%).Among these, agricultural coolies constitute 22.9%. Remaining were
housewives (28.1%), carpenter (0.2%), welding (0.2%), industrial workers and
others
             Fig:5  Occupation wise distribution of the study population
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6.2  Distribution  of  mean  Peak  Expiratory  Flow  Rate  (PEFR)  in  the  study
population
From table 13, it could be noted that mean Peak Expiratory Flow Rate
(PEFR) among males (401.13) was significantly higher than the mean PEFR of
females (306.37).
Table:13 Age and sex wise Distribution of Mean Peak Expiratory Flow
Rate(PEFR)
Age Group sex N Mean         S.D t-Value P-Value
30 to 39 yrs
M 51 459.74 78.017
11.038 <0.001
F 102 330.07 43.772
40 to 49 yrs
M 50 433.87 81.331
10.321 <0.001
F 96 304.89 47.080
50 to 59 yrs
M 35 378.42 96.339
4.819 <0.001
F 80 294.12 57.080
60 yrs and
above
M 30 263.07 97.548
0.355 0.724
F 36 270.63 62.726
Total
M 165 401.13 110.16
10.367 <0.001
F 315 306.37 54.08
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Fig: 6  Age vs Observed PEFR value in the study population( Scatter Plot)
Scatter plot above shows a negative correlation between age and PEFR
(r2 = 0.138) i.e. As age increases, PEFR decreases.
    Fig : 7  Height vs Observed PEFR Value (Scatter plot)
Scatter plot above shows a positive correlation between height and PEFR
value (r2 =0.282) i.e. As height increases, PEFR value also increases.
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6.3    Prevalence of COPD in the study population
Those having PEFR value less than 80% of the predicted value were
diagnosed to have COPD. Predicted values for this study was obtained from a study
by  Rajendra  Prasad  et  al98.  This  prediction  model  is  for  Indians  and  based  on  age,
sex & height of the individual. Formula for predicted values  are as follows,
                     For males:      -2.294 x age + 3.38 x Height in cms
                     For females:   -2.8 x age + 3.05 x Height in cms
Fig:8 --Pie chart shows that 91(19%) of the study population were having COPD
91 (19%)
389  (81%)
Fig: 8  Prevalence of COPD
COPD
No COPD
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6.3.1     Age wise distribution of COPD
Table: 14 represents the age wise distribution of COPD. Out of 480 study
participants,  91(19%)  were  found  to  have  COPD  with  95%  confidence  interval  of
14.1%  to  23.2%.Apart  from  this,  it  is  also  seen  that  as  age  increases,  COPD
prevalence also increases gradually i.e. from 6.5% among 30-39years to 43.9%
among more than 60 years age group.
                           Table : 14  Age wise distribution of COPD
Age group Total No. COPD No.(%) 95% CI
30-39 yrs 153 10 (6.5%) 3.4% - 12%
40-49 yrs 144 24 (16.7%) 10.9% - 25.3%
50-59 yrs 117 28 (23.9%) 13.9% - 37.5%
60 yrs & above 66 29 (43.9%) 29.1% - 49.6%
Total 480 91 (19%) 14.1% - 23.2%
6.3.2    Sex wise distribution of COPD
                         Table : 15  Sex wise distribution of COPD
Sex Total No. COPD No.(%) 95% CI
Males 169 62   (36.7%) 26.2% - 48.7%
Females 311 29   (9.3%) 5.5% - 12.7%
Total 480 91    (19%) 14.1% - 23.2%
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Table: 15 Shows that among the study participants, males had higher
prevalence of COPD (36.7%) than females (9.3%).
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Fig:9  Prevalence of respiratory symptoms in the study
population
percentage
In the study population, 289(60.2%) were asymptomatics (i.e. not having any
symptoms of chronic cough, chronic sputum production or dyspnoea). Among the
symptomatics (191), breathlessness was the major symptom (74.4%) followed by
cough and sputum production.(shown in fig:9)
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6.4   Distribution of risk factors in the study population
    Table: 16   Distribution of risk factors in the study population (N=480)
Risk factors Frequency percentage
Smoking status
Current smoker 55 11.5%
Ex-smoker 43 9.0%
Passive smoker 136 28.3%
Indoor air pollution from cooking fuels
Cowdung/coal/wood (biomass) 195 40.6%
Kerosene 20 4.2%
Both LPG & biomass 56 11.7%
Inadequately ventilated houses 365 76.0%
Past H/o pulmonary TB 11 2.3%
Occupation
Welding 1 0.2%
Industrial worker 2 0.4%
Carpenter 1 0.2%
Low Body Mass Index ( BMI<18.5) 47 9.8%
Table: 16 shows the distribution of various risk factors among the study population
6.4.1   Smoking status
In the study population it was observed that out of 480, 55(11.5%) were
current smokers and 43(9.0%) were ex-smokers. 28.3% were passive smokers.
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6.4.2   Indoor air pollution from cooking fuels
Majority of the study population i.e. 195 (40.6%) were using only biomass
fuels (either cowdung, coal or wood) for cooking. 56(11.7%) were using both
biomass fuel and LPG. Only 20 (4.2%) were using kerosene as cooking fuel.
6.4.3   Ventilation in the house
Almost three fourth (76.0%) were residing in inadequately ventilated houses.
6.4.4   Past history of pulmonary tuberculosis
In the study population, 11(2.3%) had past history of pulmonary TB which is
also a risk factor proved in various studies.
6.4.5   Occupation
Various occupation identified as risk factors for COPD has been shown in
Table:3. Majority of the study population were coolies and only few were involved
in risky occupations like welding (0.2%), carpenting (0.2%) and working in
industry(0.4%).
6.4.6  Body Mass Index (BMI)
Low BMI was also recognised as a risk factor for COPD in other studies. In
this study population, 47(9.8%) had low BMI of <18.5kg/m2
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6.4.7   Sex wise distribution of smoking status
Table: 18 shows the sex wise distribution of  smoking status among the study
population.  382 (79.6%) of the study population were non smokers and only 20.4%
were smokers. It is also noted that there were no female smokers. Out of 169 males,
55 (32.5%) and 43 (25.4%) were current and ex-smokers respectively.
                    Table: 17   Sex wise distribution of smoking status
Gender Current smokers Ex-smokers Non smokers Total
Male 55(32.5%) 43(25.4%) 71(42.0%) 169
Female 0 0 311 (100%) 311
Total 55 (11.5%) 43 (9.0%) 382 (79.6%) 480
6.4.8   Age at initiation of smoking
Table 18 reveals that most of the smokers (63.3%) initiated their smoking at
15-24 years age group itself. 18.4% initiated during 25-30 and only15.3% started
smoking above 30 years
      Table: 18 Distribution of smokers as per their age at initiation of smoking
Age at smoking No. Percentage among smokers
10-14 yrs 3 3%
15-19 yrs 23 23.5%
20-24 yrs 39 39.8%
25-30 yrs 18 18.4%
>30 yrs 15 15.3%
Total 98 100%
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6.4.9   Distribution of type of smoking product
 It is observed from Fig 10 that beedi smoking was predominant in both
current and ex-smokers (58.2%Vs 67.4%) compared to cigarette smoking (27.3%
Vs 20.9%).
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Fig :10  Distribution of smokers according to type of
smoking product
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6.4.10   Percentage distribution of smokers according to pack years
Pack-yrs was calculated based on the formula-{No. of cigarettes smoked per
day /  20 x duration of smoking}. Table 19 shows that 1-14 pack years of smoking
was the commonest among smokers (57 out of 98) followed by others in descending
order. Though current smokers predominate in all pack-yrs of smoking, when it
comes to ? 50 pack-yrs, it was the ex-smokers who predominate (60% exsmokers
Vs 40% current smokers).
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        Table:19 Percentage distribution of smokers according to pack years
Pack-
years
Smoking history
Total
Current smokers Ex-smokers
1-14 years 32 (56.1%) 25 (43.9%) 57
15-24 years 9 (56.3%) 7 (43.8%) 16
25-49 years 12 (60.0%) 8(40.0%) 20
? 50 years 2 (40%) 3 (60%) 5
Total 55 43 98
6.4.11   COPD Scoring among smokers using IPAG questionnaire
Table: 20 shows that 43.9% of the smokers scored in favour of COPD
 (i.e 17 or more) and among these high scorers, current smokers accounted for
51.2% in comparison to 48.8% by ex- smokers.
                Table: 20 Distribution of smokers according to COPD Score
COPD
Scoring
Current Smokers Ex smokers Total
No. Percentage No. Percentage
No.
Percentage
<17 33 60.0% 22 40.0% 55          56.1%
? 17 22 51.2% 21 48.8% 43          43.9%
Total 55 56.1% 43 43.9% 98          100%
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6.5    Association of COPD with various factors
                  Table : 21 Cross tabulation between Age and COPD
       Chi-square value= 44.550     (df = 3)          P value = 0.000 (S)
In this study, it is noted from table 21 that increasing age is significantly
associated with increased prevalence of COPD with P value =0.000
               Table : 22  Cross tabulation between sex and COPD
Sex COPD Present COPD Absent Total
Males 62 (36.7%) 107 (63.3%) 169
Females 29 (9.3%) 282 (90.7%) 311
Total 91 (19.0%) 389 (81.0%) 480
      Chi-square= 53.356          (df=1)        P value = 0.000 (S)
Table:22 shows that there was statistically significant difference in the
prevalence of OPD among males and females i.e. males showing higher prevalence
(36.7%) than females( 9.3%)
Age group COPD Present COPD Absent Total
30-39 yrs 10 (6.5%) 143 (93.5%) 153
40-49 yrs 24 (16.7%) 120 (83.3%) 144
50-59 yrs 28 (23.9%) 89 (76.1%) 117
?60yrs 29 (43.9%) 37 (56.1%) 66
Total 91 (19.0%) 389 (81.0%) 480
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                 Table:23  Cross tabulation between education and COPD
Education Level COPD Present COPD Absent Total
Illiterate 39 (22%) 138 (78%) 177
1-5th 32 (24.6%) 98 (75.4%) 130
6-12th 20 (13.3%) 130 (86.7%) 150
Degree/ others 0 23 (100%) 23
Total 91 (19.0%) 389 (81.0%) 480
      Chi-square= 12.267      (df=3)     P value = 0.007 (S)
Table  23  shows  that  22% of  illiterates  in  the  study  population  were  having
COPD. Among the literates, COPD prevalence was highest (24.6%) among primary
schoolers  i.e. 1-5th std and thereafter it decreases with increasing level of education.
This difference was found to be statistically significant.
Occupation and COPD
As shown in Fig:3, majority of the study participants were coolies (either
agricultural or non-agricultural coolies) and only 4 were involved in risky
occupation. Hence occupation was not analysed with COPD
         Table: 24 Cross tabulation between Socio Economic Status and COPD
SES COPD Present COPD Absent Total
Class I 3 (9.4%) 29 (90.6%) 32
Class II 6 (11.5%) 46 (88.5%) 52
Class III 25 (15.6%) 135 (84.4%) 160
Class IV 34 (20.0%) 136 (80%) 170
Class V 23 (34.8%) 43 (65.2%) 66
Total 91 (19.0%) 389 (81.0%) 480
     Chi-square value 15.900        (df=4)       P value = 0.003 (S)
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It is evident from table 24 that COPD prevalence was highest among class V
(34.8%). This table also expresses a significant inverse relationship between COPD
and socio economic status i.e. COPD prevalence decreases as socioeconomic class
improves.
          Table 25 Cross tabulation between smoking and COPD
Smoking status COPD Present COPD Absent Total
Current smokers 27 (49.1%) 28 (50.9%) 55
Ex smokers 27 (62.8%) 16 (37.2%) 43
Non smokers 37 (9.7%) 345 (90.3%) 382
Total 91 (19%) 389 (81%) 480
    Chi-square = 107.7     (df=2)        P value = 0.000 (S)
It is seen from table 25 that Smokers had higher prevalence of COPD
compared to non smokers. Among smokers, ex-smokers had higher prevalence than
current smokers (62.8% Vs 49.1%). These differences were found to be highly
significant
       Table 26 Cross tabulation between Pack years of smoking and COPD
Pack years of smoking COPD present COPD absent Total
Non smokers 38 (9.9%) 345 (90.1%) 383
< 20 pack years 27 (41.5%) 38 (58.5%) 65
? 20 pack years 26 (81.2%) 6 (18.8%) 32
Total 91 (19%) 389 (81%) 480
 Chi-square value = 128.185      (df=2)           P value = 0.000 (S)
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Tobacco use among smokers was evaluated on accumulative basis expressed
in pack-years. Table 26 shows that prevalence of COPD was significantly higher
among those who smoked ? 20 pack-years when compared to those who smoked
<20 pack-years (81.2% Vs 41.5%)
Table 27 Cross tabulation between COPD score and COPD among smokers
COPD score COPD present COPD absent Total
Non smokers 37 (9.7%) 345 (90.3%) 382
Smokers (< 17) 23 (41.8%) 32 (58.2%) 55
Smokers  (? 17) 31 (72.1%) 12 (27.9%) 43
Total 91 (19%) 389 (81%) 480
  Chi-square value = 119.1        (df =2)           P value = 0.000 (S)
Total number of smokers in the study population was 98. Out of this 98, 43
scored in favour of COPD i.e. ? 17 and 55 scored <17. Those who scored ? 17 had
higher prevalence of COPD (72.1%) than those who scored <17 (41.8%). This
difference was found to be statistically significant (table 27)
 Table 28 Cross tabulation between Passive smoking and COPD among non
smokers
Passive smoking COPD Present COPD Absent Total
Yes 12 (9%) 121 (91%) 133
No 25 (10%) 224 (90%) 249
Total 37 (9.7%) 345 (90.3%) 382
      Chi-square value= 0.103      (df =1)         P value = 0.749 (>0.05) (NS)
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Table 28 shows that there was no significant difference in the prevalence of
COPD among those who exposed to passive smoking and those who do not. Most of
the passive smokers i.e. 95/133 (71.4%) exposed to the smoke during adulthood.
Among these, majority have exposed from husband 75(78.9%) followed by father in
law- 2(2.1%) and others-18(18.9%).Others include son, son-in-law, brother etc.
               Table 29 Cross tabulation between cooking fuel and COPD
Cooking fuel COPD present COPD absent Total
LPG 25 (12%) 184 (88%) 209
Kerosene 1 (5%) 19 (95%) 20
Bio-fuels 56 (28.7%) 139 (71.3%) 195
LPG & Bio-fuels 9 (16.1%) 47 (83.9%) 56
Total 91 (19%) 389 (81%) 480
    Chi-square value = 21.588      df = 3       P value = 0.000 (S)
Biomass  fuels  are  cowdung,  wood  and  coal.  Table  29  shows  that  COPD
prevalence was highest among biomass fuel users (28.7%) followed by both LPG &
biomass users (16.1%), LPG alone (12%) and Kerosene fuel users (5%). This
difference was found to be highly significant (P=0.000).
Table 30 Cross tabulation between average cooking hours per day and COPD
Cooking hours/day COPD Present COPD absent Total
None 59 (33.7%) 116 (66.3%) 175
< 3 hours 20 (8.7%) 209 (91.3%) 229
? 3 hours 12 (15.8%) 64 (84.2%) 76
Total 91 (19%) 389 (81%) 480
   Chi-square value = 40.880       (df=2)           P value = 0.000 (S)
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It is evident from table 30 that those who cooked for ? 3 hours/day had
significantly higher prevalence of COPD (15.8% Vs 8.7%)
               Table 31 Cross tabulation between ventilation and COPD
Ventilation COPD present COPD absent Total
Adequate 10 (8.7%) 105 (91.3%) 115
Inadequate 81 (22.2%) 284 (77.8%) 365
Total 91 (19%) 389 (81%) 480
   Chi-square value = 10.367      (df = 1)    P value = 0.001 (S)
From  table  31,  it  could  be  inferred  that  those  who  resided  in  houses  with
inadequate ventilation had significantly higher prevalence of COPD than those who
resided in adequately ventilated houses (22.2% Vs 8.7%)
                  Table: 32 Past history of pulmonary TB and COPD
Past history of pulmonary TB COPD present COPD absent Total
Present 3 (27.3%) 8 (72.7%) 11
Absent 88 (18.8%) 381 (81.2%) 469
Total 91 (19%) 389 (81%) 480
  Chi square value = 0.507        df = 1          P value = 0.477(NS)
Table 32 shows that COPD prevalence was higher among those who had
pulmonary TB in the past (27.3%) than those who didn’t have (18.8%).But this
difference was not statistically significant.
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                 Table 33   Respiratory symptoms in relation to COPD
Symptoms COPD
Present
COPD Absent Total
Chi-square
value
P value
Chronic           yes
Cough              No
30 (57.7%)
61 (14.3%)
22 (42.3%)
367 (85.7%)
51
419
56.948
(df=1)
0.000
(<0.05)
Chronic           Yes
Sputum           No
29 (59.2%)
62 (14.4%)
20 (40.8%)
369 (85.6%)
48
422
57.471
(df=1)
0.000
(<0.05)
Breathlesness   yes
                      No
62 (33.2%)
  29 (9.9%)
125 (66.8%)
264 (90.1%)
185
285
40.187
(df=1)
0.000
(<0.05)
Symptomatics (either having chronic cough, chronic sputum or dyspnoea)
had significantly higher prevalence of COPD when compared to those who were not
having any of these symptoms respectively with P value of 0.000 (shown in
table 33).
                Table 34 Cross tabulation between BMI and COPD
BMI COPD Present COPD absent Total
< 18.5 kg/m2 15 (31.9%) 32 (68.1%) 47
18.5 – 24.99 kg/ m2 55 (20%) 220 (80%) 275
? 25 kg/m2 21 (13.4%) 137 (86.7%) 158
Total 91 (19%) 389 (81%) 480
   Chi-square value = 8.500      (df=2)            P value = 0.014 (S)
Table 34 reveals that those with low BMI (<18.5kg/m2) had significantly
higher prevalence of COPD (31.9%) when compared to others.(P=0.014).
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                  Table: 35   Multiple Logistic Regression Analysis.
Factors Beta
S.E. of
Beta
P-Value
Adiusted
OR
95% C.I. for
EXP(B)
Lower Upper
Age Group
30 to 39 yrs*
40 to 49 yrs 1.292 0.480 0.007 3.640 1.421 9.325
50 to 59 yrs 1.602 0.474 0.001 4.962 1.959 12.568
60 yrs&
above
1.627 0.530 0.002 5.088 1.800 14.385
House type
Pucca*
Kutcha -0.264 0.456 0.562 0.768 0.314 1.878
Semi pucca 0.928 0.359 0.010 2.530 1.251 5.116
Smoking
History
Non smoker*
    Current
      smoker
2.364 0.640 0.000 10.633 3.036 37.248
Ex smoker 2.931 0.687 0.000 18.742 4.880 71.980
Variables marked with * was taken as reference category.
MLR  results  (table  35)  shows  that  the  factors  causing  COPD  after
controlling the effect of other variables are advancing age group, residing in
semipucca house and smoking. The Odds of having COPD in the age group 40 – 49
years,  when  compared  to  30  –  39  years  is  3.64  times  higher  with  (95%  CI:
1.42 – 9.32) and it is statistically significant (P=0.007). Similarly, the odds for
50 -59 years is 4.96 (95% CI: 1.96 – 12.57) and 60 or more years is 5.10 (95% CI:
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1.80 – 14.38) times higher when compared to 30 – 39 years age group. These Odds
are also statistically significant. The odds of having COPD for those residing in
semipucca house when compared to pucca house is 2.53 (95% CI of 1.251- 5.116)
times higher significantly. Similarly, when compared to non smokers, current and
ex-smokers have 10.63 and 18.74 times higher odds of having COPD respectively
with significant P value of 0.000.
           DISCUSSION
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7.   DISCUSSION
This community based cross sectional study was done to estimate the
prevalence  of  COPD  among  adults  aged  30  years  and  above  and  also  to  find  out
associated risk factors of COPD like smoking, environmental tobacco smoke
exposure, exposure to biomass fuels etc among them. This study was carried out in
selected panchayat villages of Ellapuram block of Thiruvallur district.
This study included 480 adults of which 169 (35.2%) were males and
311(64.8%) were females. Majority of the study population were Hindus (94.4%).
Based on modified BG Prasad’s class for socio economic status, majority of them
belonged to class III-V (33.3%, 35.4% and 13.8% respectively) followed by 17.5%
together in class I & II.  54.4% were coolies.
To  find  out  the  prevalence  of  COPD,  peak  flow  meter  was  used  and  the
predicted values were constructed for each individual based on their age & height
using prediction models for Indians by Rajendra Prasad etal. 98 Those having
predicted values less than 80% were diagnosed as COPD as this cut-off value has a
sensitivity  of  91% and  specificity  of  82%.  in  diagnosing  COPD as  per  a  study  by
Jackson H etal.101
According to the present study findings, mean Peak Expiratory Flow Rate
(PEFR) among males was significantly higher (401.13)  than the mean PEFR of
females (306.37). The similar findings were reported by two other Indian studies
namely Singh HD and Pero 104 and Jain SK etal.105   Singh HD and Pero tabulated
the PEFR values from number of Indian studies and found that Indian males had a
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mean PEFR of 500 Litres/min ( 450-550 lpm) in contrast to Indian females who had
mean PEFR of only 395 litres/min (320-470 lpm).
The negative correlation of age with Peak Expiratory Flow Rates and
positive correlation with height found in this study is consistent with earlier studies
by V.K.Vijayan etal 106 Udwadia FE etal.107 Both the studies were done in Chennai.
Prevalence of COPD
There are conflicting prevalence estimates in the published literature. This is
mainly due to differences in methodology and definitions used to measure the
disease. For example: use of methodologies like physician diagnosed COPD, self
reported symptoms, respiratory symptoms, measurement of airflow limitation etc.
All these methods have their own advantages and limitations when it comes to field
application with different sensitivities and specificities to diagnose COPD and also
the costs. However, for epidemiological purposes ,measurement of airflow limitation
with either a Peak flow meter or spirometer remains the most useful tool to asses
COPD. It is also evident from studies108 that diagnosis of airflow limitation along
with advice to stop smoking increases the cessation rates among smokers thereby
reducing  the  progression  of  the  disease.  Hence  peak  flow  meter  was  used  in  the
present  study  and  spirometry  was  not  used  because  of  its  high  cost  and  practical
difficulties in its field application such as complex and time consuming procedure
with the requirement of maximal patient efforts.
In  this  study,  91  (19%)    were  identified  as  having  COPD which  is  almost
similar to the pilot study prevalence of 22% done among the same study population
before the conduct of the present study.
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Giovanni viegietal 57 reported a similar prevalence of 18.3%  in his study conducted
among adults > 25 years in rural area of north Italy in 2004.This prevalence was
based on clinical criteria.
In Upsala, a study involving adults aged 40 and above by Danielsson P etal82
in 2011, found almost similar prevalence of 16.2%.
Many Indian field studies done upto 1995 17,18,39,44,45-51   had reported very low
prevalence of COPD ranging from 2% to 9%.when compared to the present study.
For example :  Thiruvengadam etal17  reported  a  prevalence  of  1.9% in  males  and
1.2% in females in Chennai, Jindal etal39 in rural north India found 5% prevalence
in males & 2.7% in females,  Viswanathan& singh49  found a prevalence of  8% in
males whereas a study in rural north India by Malik 51 showed a prevalence of 9.4 %
in men & 4.9% in women. The difference in prevalence estimates between these
studies and the present study could be due to various reasons like.
1) Differences in methodology :
       For ex: most of the earlier studies in India had used questionnaire
alone.18,47-49 whereas the present study used peak flow meter in addition to
the questionnaire .For epidemiological studies, it is appropriate to use both
the questionnaire and measuring tool for airflow limitation as it may lower
the false positive rates of patient identification associated with either tool
individually.109 Moreover, the problem of misdiagnosis may occur with the
surveys based on questionnaire alone. This problem of misdiagnosis depends
on  two  factors.  One  is  the  structure  and  inherent  properties  of  the
questionnaire, and the other is the social, demographic and medical factors of
the population being studied.
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2) Differences in definition criteria:
Earlier studies100 had attempted to separate the chronic bronchitis simple
from chronic bronchitis with airways obstruction . But the term COPD includes both
due to the pitfalls of separate definitions.19 Moreover according to GOLD
guidelines,2  breathlessness  -  a  manifestation  of  airflow obstruction,  is  also  one  of
the diagnostic criteria for COPD.  But many earlier studies in India17,18,44,47-49
diagnosed COPD based on the definition of chronic bronchitis only(cough on most
of the days for 3 months in a year for 2 consecutive years ) thereby missing the
breathlessness component i.e. airflow limitation. But the present study diagnosed
COPD  based  on  peak  flow  meter  which  measures  the  airflow  limitation  (i.e
including both the components of CB,S & CB, AO) thereby contributing to the
increased prevalence of COPD. It is also proved by the fact that few earlier Indian
studies which used peak flow meter(a study by Radha etal in urban Delhi44 and  a
study in rural north India by Malik51  showed relatively higher prevalence of COPD
when compared to studies that used questionnaire alone.18,47-49
3)    Varied age groups recruited by different studies. For ex: Wig etal46 included 0-
55+ yrs, 0-70+yrs by Viswanathanetal,47   5-60+ by Thiruvengadam etal,17 3-60+ by
Radha etal,44 15-65+ by Malik51 etc. whereas the present study included the age
group of 30 and above. It is evident that COPD is uncommon in younger age group
and the inclusion of this age group will dilute the true prevalence thereby accounting
for the lower prevalence in the above said studies.19
4)    Rural-urban differences also play a major role because of the different rates of
exposure to the risk factors.
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5)   There are studies on North-south differences in prevalence estimates. Higher
prevalence estimates had been noted in south India (Tamil Nadu) in previous studies
as well. 18
6)   Moreover, these studies  in India were conducted before 1990 and hence the
high prevalence of the present study could be attributed to changes in lifestyle like
increased prevalence of both active and passive smoking , increased environmental
pollution, increased use of chemical pesticides & fertilisers in agriculture which is
also an air pollutant. Because of the alarming and growing evidences that smoking
rate is steadily increasing among Indians, it is expected that COPD prevalence rate
also increases justifying the higher prevalence of the present study.
7)    Prevalence of COPD in the present study was also considerably higher than the
prevalence of 9% in males & 5% in females reported by previous studies in India39,51
that used identical diagnostic criteria i.e  peak flow meter. This could be due to the
fact  that  prediction models for peak flow meter used in these studies were the one
designed by Malik in 1975110   and Ray D in 199318 in contrast to the present study.
The  present  study  used  the  latest  prediction  model  for  Indians  by  Rajendra  Prasad
etal98 in 2006. Moreover, the abovesaid two studies were conducted in 1990s—
almost two decades back. There are no recent studies on COPD in India using peak
flow meter to compare the prevalence estimates of the present study.
Age and COPD
In the present study the prevalence of COPD was highest among 60 years
and above (43.9%) and lowest among 30–39 years (6.5%). It has also been observed
that increasing age was significantly associated with higher prevalence of COPD
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(P  value  is  0.000).  This  finding   is  consistent  with  the  reports  by  other  studies
namely, a large population based study conducted in China by NanshanZhongetal81
reporting a p value of <0.0001, a study by Waked M etal among Lebanon adults 111
with  adjusted odds of 1.05, a prospective study on COPD by Ray D etal18 in rural
south  India,  a  community  based  cross  sectional  study  on  COPD  in  rural  India  by
SundeepSalvi etal52 (OR of  2.01)and  a  multicentric  study  in  India  by  Jindal  etal.19
Though the younger age group had a lesser prevalence compared to older age(60
and above), it is of public health importance as the younger age will be continuously
exposed to the risk factors.
Sex and COPD
The  present  study  found  a  significant  higher  prevalence  of  COPD  among
males than females (36.7% Vs 9.3%, P value=0.000. A study by Jindal SK etal19 in
India, NanshanZhong etal81 in China and SundeepSalvi etal52 also found the similar
findings.
Socioeconomic status and COPD
Lower the socio economic status higher the prevalence of COPD was the
observation made in the present study with a significant P value of 0.003. The
lowest social class (Class V) had a prevalence of 34.8%but it was only 9.4% among
the highest class (Class I). Factors like increased usage of biomass fuel for cooking ,
poorly ventilated housing, overcrowding etc., could make the lower socio economic
class people more vulnerable to the disease. The similar findings have been reported
by Viegi G etal28 and few other studies.
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Cooking fuel and COPD
As mentioned  earlier  exposure  to  biomass  fuels  (cowdung /wood/coal)  is  a
independent risk factor with special to females. 52.3% of the study population were
using biomass fuels for cooking either alone (40.6%) or in combination with LPG
(11.7%). In the present study, prevalence was significantly more among biomass
fuel users (28.7%) than those using other fuels (5% in kerosene users, 12% in LPG
users  and  16.1% in  both  LPG and  biomass  users)  with  a  P  value  =  0.000.  Similar
findings  has  been  documented  in  many studies.  A meta  analysis  on  risk  of  COPD
from biomass exposure by Guoping Hu etal in 2010112 found an higher odds (OR-
2.44 with 95% confidence interval of1.9 to 3.33) of developing COPD for those
exposed to biomass, relative to those not exposed. Ekici et al113 did a comparative
study on chronic airway diseases among non-smoking women of  40 years or more
.They split the study subjects into 2 groups based on the presence or absence of
exposure to biomass cooking in Turkey;).Their findings proved that biomass smoke
pollution is a predominant contributing factor for the development of chronic airway
diseases in non-smoking women  in rural area. Also, a study by Shengming Liu
etal34 in rural south china and by Goel S etal in India in 2007114 showed a
significant association between COPD and exposure to biomass fuel for cooking.
Average cooking hours/day and COPD
Studies have shown that COPD prevalence increases with increasing hours-
years of biomass exposure.20,62 In the present study, only women were involved in
cooking and thus exposed to biomass fuel. Though hours-years of exposure was not
calculated, same trend was seen in the present study i.e those cooking for >3hrs/day
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had a higher prevalence of 15.8% compared to those cooking < 3 hrs/day. Similarly,
a study by Priscilla Johnson etal53 among rural women of Tamilnadu reported two
times higher prevalence of COPD in women involved in cooking for >2 hrs/ day in
kitchen.
Ventilation and COPD
In the present study, inadequate ventilation was significantly associated with
the development of COPD (prevalence of 22.2% in poorly ventilated houses Vs
8.7% in adequately ventilated houses). This finding is agreeable with the findings of
study in Chinese rural area by Ran PX et al 33 who reported a odds ratio of 1.97,95%
CI = 1.06 – 2.03 for worse ventilation.
Smoking status and COPD
There  were  no  female  smokers  in  the  present  study.  Among  98  male
smokers, 55 were current smokers and 43 ex-smokers .Smokers had a higher
prevalence of 55.1% compared to non smokers (9.7%). This difference was noted to
be highly significant ( P value = 0.000). Among the smokers, ex smokers showed a
higher prevalence of 62.8% than current smokers (49.1%).The present study finding
of significant association between smoking and COPD has been consistently
observed  in  many  studies.  Smoking  as  an  etiology  of  COPD  has  been  proved  in
many international reports.4, 20,62   COPD was five times more common in smokers
as per the NHANES III survey. Sundeepsalvi etal 52 in his study, reported a higher
odds(OR of 2.34) of developing COPD for smokers. .Almost half of the current
smokers  (49.1%)  had  COPD  in  the  present  study  similar  to  46.6%  reported  by
Vandevoorde J etal64 in a case finding study in general practice in 2007. Tobacco use
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among smokers was evaluated on accumulative basis expressed in pack-years. The
present study identified a significant association of COPD with smoking exposure of
>20 pack-yrs similar to a study by Ohar JA etal in 2010.115
Symptoms and COPD
In general, symptomatics had significantly higher prevalence of COPD i.e.
64(33.5%) neccessiating the need for community based screening programme.
COPD scoring for smokers and COPD prevalence
International Primary Airways Group (IPAG) has given a COPD scoring for
smokers based on age, pack-years of smoking, respiratory symptoms, BMI etc., and
a score of ?17 was suggested as having high diagnostic value.94   The present study
used  the  same scoring  for  smokers  and  findings  was  consistent  with  IPAG cut  off
value i.e COPD prevalence was significantly higher (72.1% among those who had
scoring ? 17, compared to 41.8% among scorers of <17 with P value of 0.000
BMI and COPD
The present study also made an statistically significant observation that
lower the BMI higher the risk of developing COPD (with P value of 0.014). Those
with lower BMI (<18.5Kg/m2) had a higher prevalence of 31.9% followed by 20%
and 13.4% among normal and high BMI holders respectively. Many researchers
documented  similar  findings.  A  study  by  Lokke  A  etal  among  high  risk  adults  of
>35 yrs in Denmark,36 a study by N.K. Jain etal in Jaipur, India 72 with mean BMI
of 18.36 for males and 17.53 for females showed p value of <0.0001,  a study by
Biswajit Chakrabarti1 etal116 among >35years adults in rural west Bengal and a
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study by NanshanZhongetal in china81. Harik-Khan etal117 found a relative risk of
2.76 for developing COPD for the lowest BMI tertile compared to the highest tertile
in men.
Other risk factors
In contrast to earlier data, no significant association was seen between low
level of education, passive smoking, past history of pulmonary TB and COPD in the
present study.
             SUMMARY
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8. SUMMARY
A population based cross sectional study was done to find out the prevalence
of Chronic Obstructive Pulmonary Disease and its risk factors like tobacco smoking,
environmental tobacco smoke exposure, exposure to biomass fuel, etc among adults
aged 30 years and above in Ellapuram block of Thiruvallur district, Tamilnadu.
 A semistructured pretested questionnaire was used to collect information
regarding the socio-demographic details, risk factor exposure and symptoms.
Height, weight and Peak Expiratory Flow Rate( PEFR) were measured. Those with
PEFR < 80% of the predicted value were considered as having COPD. Predicted
PEFR values were calculated separately for males and females based on their age
and height using peak expiratory prediction model for Indians suggested by
Rajendra Prasad etal in 2006.98
The study revealed the following findings:
In our study population, 91(19%) were found to have COPD. Prevalence was
significantly higher among males (36.7%) compared to females (9.3%)
The  mean  PEFR  was  significantly  higher  among  males  (401.13)  in
comparison to females (306.37). There was negative correlation between age and
PEFR and positive correlation with height.
Increasing age and male sex was significantly associated with the
development of the disease with p value of =0.000. Lower the socio economic status
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higher the prevalence of COPD was the observation made in the present study with a
significant P value of 0.003.
The  prevalence  of  COPD among those  exposed  to  biomass  smoke  was  the
highest (28.7%) followed by exposure to both biomass and LPG ( 16.1%) and
exposure to LPG alone( 12%). This difference was found to be highly significant ( P
value = 0.000). Similarly, those involved in cooking for > 3 hours / day had
significantly higher prevalence of COPD (15.8%) than those involved for <3 hours /
day (8.7%) with a p value of 0.0001
Similar to other studies, the present study also found a extremely significant
association between smoking and COPD (P value=0.000). Among the smokers,
those who smoked >20 pack-years had a significant higher prevalence of COPD
compared to <20 pack-years smokers (81.2% Vs 41.5%)
All respiratory symptoms like chronic cough, chronic sputum and persistent
and progressive dyspnoea were significantly associated with the development of
COPD.
COPD  scoring  was  done  for  smokers.  COPD  prevalence  was  significantly
higher among those who scored in favour of COPD i.e.? 17.
COPD  was  highly  prevalent  among  those  with  low  body  mass  index
compared to those having normal BMI as documented in many Indian as well as
international studies.
All other factors like low education level, passive smoking, past history of
pulmonary TB were not significantly associated with COPD in the study group.
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Thus, this study establishes the fact that COPD is highly prevalent among
adults in rural area which is mainly due to tobacco smoking and biomass exposure.
For practitioners, the results call for a high index of suspicion of COPD in persons
aged 30 years and above with substantial exposure to risk factors especially in
underweight individuals. For health policy makers, the present study findings urge
the  development  of  preventive  programs  failing  which  the  burden  of  COPD
increases resulting in increased mortality, morbidity and economic burden. The
baseline prevalence information provided in this study also paves the way for future
cross-sectional studies that can be used to evaluate an intervention or to make
comparisons with other populations to frame an intervention especially for biomass
exposure.
           LIMITATIONS
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9.   LIMITATIONS
1) Spirometry, the gold standard diagnostic tool for COPD, was not used in
this study due to impracticality and non affordability. Alternatively, peak
flow meter with cut-off value having 91% sensitivity and 82% specificity
in diagnosing COPD was used.
2) The diagnostic criteria for COPD based on Peak expiratory flow rate (
PEFR) can be questioned among elderly individuals as PEFR may be
normally reduced in these people as a function of aging. However this
problem can also be encountered while using gold standard (spirometric)
definition of FEV1/FVC less than 70% 118
3) Though the present study used IPAG questionnaire to rule out asthma
clinically, it did not asses IgE level or bronchodilator reversibility to
distinguish asthma from COPD.
4) The present study was done among adults of rural area only which limits
the generalizability of the findings to the urban areas.
RECOMMENDATIONS
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10.   RECOMMENDATIONS
The following are the recommendations from the findings of the study.
1) The higher prevalence noted in this study highlights the need for
enhanced community based screening programme for secondary
prevention of COPD among adults.
2) Almost 52.3% of the study population were using biomass fuel either
alone  or  in  combination  with  other  fuels  and  exposure  to  this  biomass
was found to be significant risk factor of COPD. Hence attention should
be focussed on encouraging the use of cleaner fuels, improved stoves
which reduces the smoke considerably and on adequate ventilation. But it
needs combination of public policy, national resources, cultural changes
and community participation.
3) Apart  from  this,  there  is  a  need  for  awareness  programme  among  the
people regarding the use of chimneys,  changes in behaviour like drying
wood before using it as a fuel and using a lid for the cooking utensil
while cooking so as to increase the combustion efficiency.
4) As substantial proportion of asymptomatics (9.3%) too had COPD,
health education regarding risk factor reduction should be paid attention
i.e. resources should be aimed at smoking cessation etc. Cessation
facilities need to be widely available and adequately publicised.
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5) Almost 50% of the smokers in the study population had COPD and they
were still smoking, therefore at increased risk of progression to more
severe disease. Early diagnosis and prompt intervention in this
population is very important as it is evident that diagnosis of airflow
obstruction may help to optimise smoking cessation.
6) Substantial proportion of the smokers in the study population initiated its
use in early ages (15-24) and hence the prevention programme especially
needs to address the adolescents..
7) There is a need for further studies to explore the role of nutritional
factors in the development of COPD as low BMI was also significantly
associated with COPD. Intake of adequate diet should also be
emphasised .
8) There is a need for uniform standards for diagnosing COPD in
epidemiological surveys.
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ANNEXURES
   ANNEXURE I
INFORMATION SHEET
Title of Dissertation
A Cross sectional study on Chronic obstructive pulmonary disease
(COPD) among adults aged 30 years above in Ellapuram Block, Thiruvallur
District, Tamilnadu, 2012.
COPD  is  one  of  the  chronic  respiratory  diseases  with  high  mortality  and
morbidity worldwide. In India, at present, approx 8-10% of the adult population are
affected by the disease. But it is said that prevalence is increasing especially in
developing countries like India due to increased use of biomass fuels, tobacco
smoking etc.
Many die due to its complications like respiratory or cardiac failure. These
complications and subsequent deaths can be prevented by early diagnosis and
prompt intervention like treatment, stopping exposure to risk factors.
The purpose of this study is to diagnose cases of COPD easily with the help
of certain special tests. We request you to participate in the study and we ensure that
the privacy of your details given in the research will be maintained confidentially
throughout the study. In the event of any publication or presentation resulting from
the research, no personally identifiable information will be shared.
Taking  part  in  this  study  is  voluntary.  You  are  free  to  decide  whether  to
participate in this study or to withdraw at any time. Your decision will not result in
any loss of benefits to which you are otherwise entitled.
The  results  of  the  study  may  be  intimated  to  you  at  the  end  of  the  study
period or during the study if anything is found abnormal which may aid in the
management or treatment.
Signature of investigator Signature of Participant
>Ôk_ >V^
>tµÂV‚Ω_, ]Úk^jÏ \Vk‚¶D, ®_ÈVA´D √z]l_ kE¬zD 30
kBm¬z º\u√‚¶ gı/ÿ√ı ÷Ú √Vo™ÏÔπ¶xD ∑kVƒ¬zwVF ∂Á¶©A
ƒD√Õ>\V™ ºÂVl[ (COPD) √V]©A z§›> gF°.
COPD ®[√m OÁX´_ ƒD√Õ>\V™ ºÂVFÔπ_ Œ[Æ cÈÔ·s_ ÷Õ>
ºÂVF¬z, ∂]Ô©√ΩBV™ clˆw©AD c¶_ √V]©AD ∞u√|˛≈m. ÷Õ]BVs_
>uº√Vm ∑\VÏ 8-10 ƒ>sˇ>D kÁ´lÈV™ \¬Ô^ ÷Õ> ºÂVBV_
√V]¬Ô©√‚|^·™Ï. º\KD, ÷Õ> ºÂVBV_ √V]¬Ô©√|kˆ[ ®ıË¬ÁÔ
∂]ÔVˆ¬Ô©º√Vk>VÔ cÈÔ ∑ÔV>V´ ∂§¬ÁÔ z§©∏|˛≈m - (z§©√VÔ ÷Õ]BV
º√V[≈ k·ÏﬂE ∂Á¶•D ÂV|Ôπ_). ÷ÕÂV|Ôπ_, z§©√VÔ ˛´V\A´∫Ôπ_,
∂]Ô©√ΩBVÔ √B[√|›m©√|D ƒÁ\B_ ®ˆkV•kV™ s≈z / \V‚|ﬂƒV™D /
÷ÁÈÔ^ º√V[≈ÁkÔπoÚÕm ÿkπºBÆD AÁÔl™VKD, AÁÔ∏Ω¬zD,
√w¬Ô›]™VKD ÷ÕºÂVF ∂]Ôˆ¬˛≈m.
÷Õ> ºÂVl[ ∏[sÁ·°Ô·V™ OÁ´X´_ \uÆD ÷Ú>B ÿƒBow©√V_
∂]Ô \¬Ô^ ÷≈¬˛[≈™. g´D√ Ô‚¶›]ºÈºB ÷Õ> ºÂVÁB Ôı¶§Õm, cˆB
E˛ﬂÁƒ kw∫zk]™V_, ÷ÀkV≈V™ ∏[sÁ·°ÔÁ·•D, clˆw©AÔÁ·•D
>sÏ¬ÔÈVD, EÈ E≈©A √ˆºƒV>Á™Ôπ[ JÈD (¨¬ Aº·V *‚¶Ï ÔÚs) (Peak
Flow Meter) ÷Õ> ºÂVÁB ®π]_ Ôı|∏Ω›> g´VBxΩ•D ®[√º> ÷Õ>
g´VFﬂEl[ ºÂV¬Ô\VzD.
¿∫Ô”D ÷Õ> g´VFﬂEl_ √∫ºÔuÔ sÚDA˛º≈VD. ÷Õ>
g´VFﬂEl_ >∫Ô·m ºÂVl[ gFk§¬ÁÔºBV ∂_Èm E˛ﬂÁƒºBV
√V]©A¬z ∞u√¶Vm ®[√Á>•D ÿ>ˆs›m¬ ÿÔV^˛º≈VD.
÷Õ> g´VFﬂEl[ xΩ°ÔÁ· \uÆD ÔÚ›m¬ÔÁ· ÿkπl|D º√Vº>V
∂_Èm g´VFﬂEl[ º√Vº>V, >∫Ô·m ÿ√BÁ´ºBV ∂_Èm
∂Á¶BV·∫ÔÁ·ºBV ÿkπl¶ \V‚º¶VD ®[√Á>•D ÿ>ˆs›m¬ ÿÔV^˛º≈VD.
÷Õ> g´VFﬂEl_ √∫ºÔu√m >∫Ô”Á¶B ÿƒVÕ> sÚ©√›][ º√ˆ_
>V[ ÷Ú¬˛≈m. º\KD ¿∫Ô^ ®ÕºÂ´xD ÷Õ> g´VFﬂEloÚÕm sÈÔÈVD
®[√Á>•D ÿ>ˆs›m¬ ÿÔV^˛º≈VD.
÷Õ> E≈©A √ˆºƒV>Á™Ôπ[ xΩ°ÔÁ·, g´VFﬂEl[ º√Vº>V ∂_Èm
g´VFﬂEl[ xΩs[ º√Vº>V >∫Ô”¬z ÿ>ˆs¬Ô©√|D ®[√Á>•D
ÿ>ˆs›m¬ ÿÔV^˛º≈VD.
ANNEXURE II
INFORMED CONSENT FORM
Title of the Dissertation:
A CROSS SECTIONAL STUDY ON PREVALENCE OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE AMONG ADULTS AGED 30 YRS
AND ABOVE IN ELLAPURAM BLOCK OF THIRUVALLUR DISTRICT,
TAMILNADU, 2012
Name of the Participant: Age/Sex:
Name of the Participant’s Parent: Age/Sex:
Participant ID               : Date:
(1) I  have  been  explained  in  detail  about  the  study  and  its  procedure.  I  confirm
that I had completely understood the study and have had the opportunity to ask
questions.
(2) I understand that my son/daughter’s participation in the study is voluntary and
that my son/daughter is free to withdraw at any time, without giving any
reason, without their medical care or legal rights being affected.
(3) I understand that the principal investigator, others working on the
investigator’s behalf, the Ethics Committee and the regulatory authorities will
not  need  my permission  to  look  at  my son/daughter’s  health  records  both  in
respect of the current study and any further research that may be conducted in
relation to it, even if they withdraw from the trial. I agree to this access.
However I understand that my identity or my son/daughter’s identity will not
be revealed in any information released to third parties or published.
(4) I agree not to restrict  the use of any data or results that  arise from this study
provided such a use is only for scientific purpose(s).
(5) I agree to my son/daughter taking part in the above study.
    ----------------------------------                           --------------------------------
      Name of the Participant                                Signature or thumb impression
of the Participant
  ----------------------------------             ---------------------------------------
     Name of the investigator                               Signature of the investigator
Œ©A>_ ÔΩ>D
>tµÂV‚Ω_, ]Úk^jÏ \Vk‚¶D, ®_ÈVA´D √z]l_ kE¬zD 30
kBm¬z º\u√‚¶ gı/ÿ√ı ÷Ú √Vo™ÏÔπ¶xD ∑kVƒ¬zwVF ∂Á¶©A
ƒD√Õ>\V™ ºÂVl[ (Chronic Obstructive Pulmonary Disease - COPD) √V]©A
z§›> gF°.
ÿ√BÏ : kBm / √Vo™D
ºƒÏÁÔ ®ı : º>] :
÷Õ> g´VFﬂEl[ sk´∫ÔÁ·¬ ÿÔVı¶, >Ôk_ >VÁ·© ÿ√uÆ¬
ÿÔVıº¶[.
÷Õ> g´VFﬂEl[ sk´∫Ô”D, ∂>[ ºÂV¬ÔxD xøÁ\BVÔ ®™¬z
ÿ>πkVÔ s·¬Ô©√‚¶m.
®™¬z s·¬Ô©√‚¶ s≠B∫ÔÁ·, ÂV[ AˆÕm ÿÔVı| ®™m
ƒD\>›Á>› ÿ>ˆs¬˛º≈[. ®™¬z, ¨¬ Aº·V *‚¶Ï (Peak Flow Meter) ®[≈
ÔÚsl[ JÈD OÁ´X´ÁÈ √ˆºƒV>Á™ ÿƒFm¬ ÿÔV^· ƒD\>D.
÷Õ> g´VFﬂEl_, ∏≈ˆ[ WÏ√Õ>t[§, ®[ ÿƒVÕ> sÚ©√›][ º√ˆ_
>V[ √∫z ÿ√Æ˛º≈[. \uÆD ÷Õ> g´VFﬂElÈ ÷ÚÕm ®ÕºÂ´xD sÈÔÈVD
®[√Á>•D, ∂>™V_ ®Õ> √V]©AD ∞u√¶Vm ®[√Á>•D ÂV[ AˆÕm
ÿÔVıº¶[.
ÂV[ ®[–Á¶B ∑B WÁ™°¶–D \uÆD xø ∑>Õ]´›m¶–D ÷Õ>
\Ú›mk g´VFﬂEl_ ®[Á™ ºƒÏ›m¬ ÿÔV^· ƒD\]¬˛º≈[.
g´VFﬂEBV·Ï \uÆD ∂kÁ´ﬂ ƒVÏÕ>kÏÔº·V, ÿÂ§xÁ≈¬zø
cÆ©∏™ÏÔº·V ÂV[ ÷Õ> g´VFﬂEl_ ÷ÚÕm sÈ˛™VKD, ®[–Á¶B
∂–\]l[§ ®™m >Ôk_ÔÁ·, ÷Õ> g´VFﬂE¬ºÔV, ÷m ÿ>V¶Ï√V™ ºkÆ
g´VFﬂEÔ”¬ºÔV, √B[√|›]¬ ÿÔV^· xΩ•D ®[Æ AˆÕm ÿÔVı| ƒD\>D
∂π¬˛º≈[. g™VKD ®[–Á¶B ∂Á¶BV·D ÿkπl¶©√¶\V‚¶Vm ®[Æ
AˆÕm ÿÔV^˛º≈[.
÷Õ> g´VFﬂEl[ >Ôk_ÔÁ·•D, xΩ°ÔÁ·•D, ∂§sB_
ºÂV¬Ô›]uÔVÔ √B[√|›mk>uz ÂV[ ∂–\]¬˛º≈[. ÂV[ ÷Õ> g´VﬂEl_
√∫z ÿ√≈ xø\™m¶[ ƒD\]¬˛º≈[.
√∫ºÔu√kˆ[ ÿ√BÏ √∫ºÔu√kˆ[ ÁÔÿBV©√D
(∂_Èm) Ô‚Á¶s´_ º´ÁÔ
gFkV·ˆ[ ÿ√BÏ gFkV·ˆ[ ÁÔÿBV©√D
ƒV‚El[ ÿ√BÏ ƒV‚El[ ÁÔÿBV©√D
÷¶D : º>] :
ANNEXURE III
QUESTIONNAIRE
A)  SOCIO DEMOGRAPHIC DETAILS:
1) Name :
2) Age :
3) Sex :
4) Religion : ?Hindu ?Christian ? Muslim ?Others
5) Address :
6) Education : ??Illiterate ??I - V Std
??VI – XII Std ??Degree
? ? ? ? ??PG Degree ??Others
7) Occupation : ??Housewife ??Coolie
??Agricultural ??Carpenter
??Welding ??Industrial Worker
??Others (if, specify type of industry, Protection offered)
8) Total monthly income of the Family : ________________________
9) Total members of the Family : ________________________
10) Type of House : ?Kutcha ?Semipucca
?Pucca ?Others
11) No. of rooms in the house : ?One ?Two
? Three ? Four
B)  HISTORY REGARDING EXPOSURE TO RISK FACTORS:
i)  Indoor Air Pollution
12)    Do you have separate kitchen
in your house : ?Yes ?No
13)  What type of fuel used
for cooking? : ?LPG
?Kerosene
?Solid Fuels (Cow Dung, Coal, Wood)
?Both LPG & biomass
?Others
14)  Do you self Cook? : ?Yes ?No
15)  If yes, total duration of
cooking in life so far : ?< 10 yrs
?10 - 15 years
? ? ? ? ? ? ?> 15 yrs
16)  Average Hours of
Cooking per day : ?< 3 hrs ?> 3 hrs
17)  Adequate ventilation in
the kitchen : ?Present ?Absent
ii)  Smoking History:
18)  Are you a,
? ??Current Smoker
(or)
??Ex-Smoker (Smoked atleast one cigarette per day for one year and
stopped smoking for more than a month)
(or)
??Non Smoker
19)  If Current or Ex-Smoker,
a) What do you / did you use : ?Cigaratte?Beedi
?Both ?Others
b) Starting age of smoking :
            c) How many cigar/beedi per day?                 :
            d) Smoking for how long?                              :
20)       Have you exposed to passive smoking : ?Yes ? No
21)  If yes,
               a) exposed from whom?                             :
               b) exposed in childhood/adulthood/both     :
iii)   Outdoor Air Pollution:
22)        Any industry near by your residence : ?Yes ?No
iv)  Did u have pulmonary TB in the past ?           : ?Yes ?No
C)     TREATMENT HISTORY:
23)   Are you on any respiratory treatment currently? : ?Yes ?No
D)  HISTORY REGARDING COPD SYMPTOMS:
24)       Are you having chronic cough ?       : ?Yes ?No
 Asses by asking following three questions
     24A. Are there months in which you cough on most days?      : ?Yes ?No
               [If yes, ask both Questions 24B & 24C; If no, skip to Question 26]
     24.B. Do you cough on most days for as much as three
months each year?                                               : ?Yes ?No
 24.C. For how many years have you had this cough?           : Less than 2 years ??
 2-5 years ??
More than 5 years ???
?
  If yes, to all three questions, mark chronic cough as YES or otherwise , mark it as NO
?
25)      If cough present, does weather affect your cough?           : ?Yes ?No
26)       Do you have chronic sputum  production ?       : ?Yes ?No
             Asses  by asking following three questions
     26A. Are there months in which you have this sputum on most days? Yes ??
[If yes, ask both Questions 26B & 26C; If no, skip to Question 27] No ??
     26.B. Do you bring up this sputum on most days for as much as three    Yes ??
months each year?                                                                                     No ??
? ?
     26.C. For how many years have you had this sputum?   Less than 2 years??
 2-5 years ??
 More than 5 years??
?
           If yes, to all three questions, mark chronic sputum as YES or otherwise , mark it NO.
27)  Do you cough up sputum as 1st thing in the morning?: ?Yes ?No
28)  Do you produce sputum in absence of cold?  : ?Yes ?No??
29)  Do you have breathing difficulty ? : ?Yes ?No
30)  If yes, (based on Modified Medical Research Council questionnaire for
assessing severity)
            Do you get breathless with strenuous exercise?     : ?Yes ?No
                                                            (or)
           Do you get breathless while walking up flight of stairs : ?Yes ?No
(or)
           Do you stop for breath when walking on own pace on the level:?Yes ?No
(or)
 Do you stop for breath after walking 100 mts/
few minutes on the level : ?Yes ?No
(or)
 Do you become breathless even while dressing/undressing  :?Yes ?No
 b) Is it present every day? : ?Yes ?No
c) Is it getting worse over time? : ?Yes ?No
            d) Have u ever been hospitalized for breathing problem?   :?Yes ?No
31)   Do you wheeze? : ?Yes ?No
E)  HISTORY TO RULE OUT ASTHMA:
1.  Do you have any allergy to dust/pollen?  ; ?Yes ?No
2.  In last 1 year, have you woken up at night at any time due to –
 - attack of cough ?Yes ?No
- feeling of chest tightness: ?Yes ?No
- breathing difficulty :?Yes ?No
F) COPD SCORING - For Smokers based on symptoms and risk factors as
per international primary care airways group (2005) – a guide for
primary care physicians.
If smoker and no prior diagnosis of respiratory disease / not on any respiratory
treatment
Question Response Choices Points
1.  What is your age in years? 40-49 years
50-59 years
60-69 years
70 years or older
0
4
8
10
2. No. of cigarettes smoked per day
    (ex-smoker) or No. of cigarettes smoking per day
    currently. (Current smoker)___________
    Total duration of smoking in years. ________
     Packs per day = cigarettes per day/ 20 per pack
     Pack-years = packs per day X years smoked
0-14 pack-years
15-24 pack-years
25-49 pack-years
50+ pack-years
0
2
3
7
3.  Weight in kilograms ________
     Height in meters __________
      BMI = weight in kg/(height in m)2
BMI < 25.4
BMI 25.4-29.7
BMI > 29.7
5
1
0
4.  Does the weather affect your cough? Yes
No
I do not have a
cough
3
0
0
5.  In the absence of cold, do you produce sputum
     while coughing.
Yes
No
3
0
6. Do you usually cough up phlegm (sputum) from
     your chest first thing in the morning?
Yes
No
0
3
7. How frequently do you wheeze? Never
Occasionally or
more often
0
4
8. Do you have or have you had any allergies? Yes
No
0
3
Total Score
F)  CLINICAL EXAMINATION:
Height :  --------- cms
Weight : ---------- kg
Peak Expiratory flow rate
a) Predicted Value
b) Observed
Value
c) % of Predicted
Value (b/a x 100)
d) Inference
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ANNEXURE IV
SOCIO ECONOMIC CLASS BASED ON MODIFIED B.G.PRASAD’S
CLASSIFICATION
   As  the  study  was  done  in  rural  area,  modified  B.G.  Prasad’s  classification
was used for socio economic classification. The calculation was done as follows:
 Consumer Price Index for rural labourers in Tamilnadu for the month of
October 2012 =661
       Multiplication factor = Value of consumer price index X 4.93/100
                                                 = 661 X 4.93/100
                                                 = 32.59
       Modified BG Prasad’s classification for october 2012 = Percapita income in
1961 X multiplication factor
CLASS
OLD
CLASSIFICATION 1961 FOR OCTOBER 2012
I 100 & above 3259 & above
II 50-99 1630-3258
III 30-49 978-1629
IV 15-29 489-977
V <15 <489
ANNEXURE – V
ANNEXURE – VI
LIST OF TOTAL VILLAGES IN ELLAPURAM BLOCK
S.No Village Name Total Population
Cumulative
Population
1 Enambakkam 1433 1433
2 Kalpattu 2030 3463
3 Malandur 1651 5114
4 Mambalam 1508 6622
5 Vadamadurai* 6472 13094
6 Vengal 4942 18036
7 Pagalmedu 1266 19302
8 Punapakkam 1575 20877
9 Sembedu 2795 23672
10 Athangikavanoor 1064 24736
11 Kilambakkam 1285 26021
12 Alinjivakkam 1443 27464
13 Athivakkam 1145 28609
14 Alappakkam 958 29567
45 Tiruneli 876 30443
16 Akarapakkam 1450 31893
17 Maduravaral 997 32890
18 Panapakkam82 1508 34398
19 Periyapalayam* 7120 41518
20 Kannigaipair* 5134 46652
21 Kummarapettai 3506 50158
22 Panayancheri 1387 51539
23 Poochiathipattu 1974 53513
24 Ayalancheri 2699 56212
25 Guruvayal 2882 59094
26 Soothupakkam 776 59870
27 Latchivakkam 2100 61970
28 Palavakkam 3046 65016
29 Tharatchi 3340 68356
30 Senjiagaram 1308 69664
31 Thamaraipakkam 891 70555
32 Perandur 2498 73053
33 Panapakkam43 2018 75071
34 Tholaivedu 1198 76269
35 Kakkavakkam 1556 77825
36 Thumbakkam 857 78682
37 Chennankaranai 1836 80518
38 Vannankuppam 1386 81904
39 Athupakkam 2684 84588
40 Thandalam 1451 86039
41 Sulaimani 2173 88212
42 Senkarai 1142 89654
43 Amirthanallur 972 90626
44 Kannigapuram 1854 92480
45 Koduveli 1973 94453
46 Kommangamedu 1890 96343
47 Magaral 1935 98278
48 Mangakaranai 2404 100682
49 Neiveli 1557 102239
50 Perumudivakkam 658 102897
51 Purivakkam 1783 104680
52 Thamaraipakkam 5465 110145
53 Thirukandalam 4544 114689
Villages marked in bold letters were the selected clusters for this study
out of total clusters.
Those village marked with * = 2 clusters in that same village.
Totally 24 clusters selected for this study.
ANNEXURE VII
KEY TO MASTER CHART
Variable Label Coding
S.No. Serial Number 1,2 etc
Age Age of the participant 30,31,32etc
Sex sex 1=Male      2=Female
Cluster_no. Cluster number to which the
participant belongs
1,2,3 etc
Religion Religion 1= Hindu       2=Christian
3=Muslim      4= Others
Education Education of the participant 1= Illiterate    2 = I - V Std
3=VI – XII Std 4 = Degree
5 = PG Degree    6=Others
Occupation Occupation of the
participant
1=Housewife   2=Coolie
3=Agricultural 4=Carpenter
5=Welding
6=Industrial Worker
7= Others
Income Total income of the family
Members Total members of the family
House_type Type of house 1= Kutcha 2=Semipucca
3=Pucca   4=Others
Rooms No.of rooms in the house
kitchen Separate kitchen in the
house
1=Yes         2=No
Cook_fuel Type of cooking fuel used 1=LPG         2=Kerosene
3=Solid Fuels (Cow Dung,
Coal, Wood)
4=Both LPG & biomass
Selfcook Self cooking at home 1=Yes         2=No
Cook_Dur Total duration of cooking 1= < 10 yrs
2=10 - 15 years
3=  > 15 yrs
Cook_Hrs Cooking hours/ day 1= < 3 hrs      2 =  > 3 hrs
Ventilation Adequate ventilation in
kitchen
1= Present   2=Absent
Smoke_H/o Smoking history of the
participant
1=Current Smoker
2=Ex-Smoker
3=Non Smoker
Smoke_What Type of smoking product
used
1=Cigaratte  2=Beedi
3=Both         4=Others
Age_Smoke Starting age of smoking
Smoke_no. No.of cigarette/bidi
smoked/day
Smoke_Dur Total duration of smoking
P_smoke Exposure to Passive
smoking
1=Yes    2= No
Pass_whom From  whom exposed to
passive smoking
Pass_when When exposed to passive
smoking
1= adulthood  2= childhood
3= both
Industry Presence of industry nearer
to house
1=Yes    2= No
Resp_Tt Respiratory treatment
undergone already
1=Yes    2= No
Past_tb Past history of pulmonary
Tuberculosis
1=Yes    2= No
Chr_cough History of chronic cough 1=Yes    2=No
weather Weather affecting the cough 1=Yes    2= No
Chr_sputum History of chronic sputum
production
1=Yes    2= No
morning Sputum production in the
morning
1=Yes    2= No
No_cold Sputum production in the
absence of cold
1=Yes    2= No
Breath_diff Breathing difficulty 1=Yes    2= No
Grading Grading of breathlessness 1/2/3/4/5
Breath_daily Presence of breathlessness
daily
1=Yes    2= No
Breath_worse Worsening of breathlessness
over time
1=Yes    2= No
hospital Hospitalised for
breathlessness
1=Yes    2= No
wheeze History of wheezing 1=Yes    2= No
Allergy History of allergy 1=Yes    2= No
wakeup Wake up at night due to
cough or breathlessness
1=Yes    2= No
COPD score COPD scoring for smokers  1= <17      2 =  ?17
Ht Height in centimetres
Wt Weight in Kilograms
Pred_value Predicted value of PEFR
Obs_value Observed value of PEFR
%pred % of predicted value
Inference Inference  Normal /obstruction
1 35 F 1 1 1 2 15000 6 3 2 2 2 1 1 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 1 2 0 147 57 350 310 88 Normal
2 38 F 1 1 1 2 2000 6 3 1 2 3 1 1 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 1 1 2 2 1 2 0 151 56 354 300 85 Normal
3 44 F 1 2 2 2 3000 3 2 1 1 1 1 1 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 1 2 2 2 1 2 0 146 63 322 310 96 Normal
4 60 F 1 1 1 2 3000 5 1 1 2 3 2 0 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 145 51 265 280 105 Normal
5 55 F 1 1 1 2 1500 4 3 3 1 4 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 156 60 321 390 121 Normal
6 65 F 1 3 2 7 3000 2 2 2 1 4 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 2 1 2 2 1 2 0 152 47 281 250 89 Normal
7 38 F 1 1 1 1 3000 4 2 4 1 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 1 1 1 1 2 1 2 1 2 2 2 2 2 0 151 65 354 330 93 Normal
8 45 F 1 1 2 2 2000 5 1 1 2 3 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 146 48 319 320 100 Normal
9 37 F 1 1 2 2 36000 4 3 2 2 3 1 1 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 1 2 2 1 2 0 153 55 363 300 83 Normal
10 47 M 1 1 2 2 3000 6 3 1 2 3 2 0 0 2 1 2 27 10 20 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 162 52 440 320 73 Obstruction
11 55 M 1 1 1 2 3000 7 3 1 2 3 2 0 0 2 1 2 25 24 30 2 0 0 2 1 2 1 1 1 1 1 1 4 1 1 2 1 1 1 8 157 36 404 310 77 Obstruction
12 43 M 1 1 3 7 19000 7 2 3 1 1 2 0 0 2 3 0 0 0 0 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 22 163 62.5 452 440 97 Normal
13 60 M 1 1 1 3 24000 3 1 1 2 3 2 0 0 2 2 2 15 24 43 2 0 0 2 2 2 1 2 1 2 1 1 3 1 2 1 1 2 2 8 156 48 389 180 46 Obstruction
14 48 M 1 1 3 2 36000 4 1 1 2 3 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 29 155 59 413 380 92 Normal
15 60 M 1 1 2 2 4000 3 3 1 2 3 2 0 0 2 2 3 10 15 50 2 0 0 2 2 2 2 0 0 0 0 1 2 1 1 1 1 2 2 0 163 59 413 240 58 Obstruction
16 30 M 1 1 3 2 4000 3 2 1 2 3 2 0 0 2 1 1 25 4 5 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 30 167 67 495 380 77 Obstruction
17 60 M 1 1 1 2 4000 6 2 2 2 3 2 0 0 2 1 2 15 12 45 2 0 0 2 2 2 1 2 1 2 1 2 0 0 0 0 0 1 1 11 156 47 390 260 67 Obstruction
18 35 F 1 1 1 3 2000 4 3 1 2 1 1 2 1 2 3 0 0 0 0 1 3 3 2 1 2 1 1 1 1 1 1 3 1 1 2 1 2 1 22 154 60 372 300 81 Normal
19 58 M 1 1 1 7 500 1 1 0 0 0 0 0 0 0 2 1 26 15 32 2 0 0 2 1 2 2 0 0 0 0 1 3 1 1 2 1 1 1 0 160 50 408 200 49 Obstruction
20 42 F 1 1 1 3 1800 2 2 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 21 143 50 318 360 113 Normal
21 40 F 2 1 1 3 1500 3 2 4 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 160 56 376 310 82 Normal
22 32 F 2 1 2 3 3000 4 1 1 2 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 2 0 0 0 0 0 2 2 0 154 55 380 430 126 Normal
23 50 F 2 1 2 3 5000 6 3 2 1 3 2 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 1 1 2 1 1 2 0 154 60 330 220 67 Obstruction
24 47 F 2 1 3 3 4000 4 3 2 2 3 1 3 1 1 3 0 0 0 0 1 3 1 2 2 2 2 0 0 0 0 1 1 1 2 2 1 1 2 0 154 56 338 330 98 Normal
25 55 F 2 1 1 3 12000 11 3 4 2 3 2 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 62 313 260 83 Normal
26 37 F 2 1 1 2 4000 5 3 2 1 3 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 138 45 317 275 87 Normal
27 57 M 2 1 3 3 5000 3 3 3 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 1 1 2 0 0 1 2 1 2 2 1 2 2 0 160 54 410 460 112 Normal
28 50 F 2 1 1 1 2000 4 3 2 1 2 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 1 1 2 2 2 2 0 147 60 308 260 84 Normal
29 53 M 2 1 4 7 80000 3 3 1 1 2 0 0 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 65 437 390 89 Normal
30 45 F 2 2 1 2 4000 5 3 1 2 3 2 0 0 2 3 0 0 0 0 1 1 1 2 2 2 1 2 1 2 2 1 3 1 1 2 1 1 2 0 148 55 325 310 95 Normal
31 50 F 2 1 1 3 7000 8 3 4 1 4 1 2 1 2 3 0 0 0 0 1 4 2 2 2 2 2 0 0 0 0 1 3 1 2 2 1 1 1 0 153 60 327 140 43 Obstruction
32 39 M 2 1 3 3 3000 3 3 4 1 4 2 0 0 1 3 0 0 0 0 1 3 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 170 50 486 460 95 Normal
33 30 F 2 1 2 6 3500 2 1 1 2 3 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 139 62 340 300 88 Normal
34 36 F 2 1 3 1 3000 4 1 1 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 55 369 400 108 Normal
35 42 F 2 1 1 2 4000 7 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 55 352 300 85 Normal
36 55 F 2 1 3 3 3000 4 3 2 2 1 1 3 1 2 3 0 0 0 0 1 0 0 2 2 2 2 0 0 0 0 1 1 1 1 2 2 2 2 0 151 60 306 250 82 Normal
37 32 F 2 1 3 3 2000 4 1 1 1 4 1 2 1 2 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 140 58 337 320 95 Normal
38 60 F 2 1 1 1 3000 5 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 1 2 2 0 156 54 308 165 54 Obstruction
39 30 F 2 1 2 1 2000 2 3 2 1 3 1 2 2 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 1 1 2 0 148 52 367 350 95 Normal
40 31 F 2 1 3 7 7000 4 2 2 2 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 58 386 400 103 Normal
41 52 F 3 3 1 1 5000 4 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 148 55 305 330 108 Normal
42 47 F 3 1 1 3 2000 2 1 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 1 2 0 160 62 356 290 81 Normal
43 35 F 3 1 1 3 2000 5 3 3 1 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 66 347 330 95 Normal
44 30 F 3 1 3 3 2000 4 3 1 2 4 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 58 389 350 90 Normal
45 60 F 3 1 1 1 1000 5 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 1 1 2 1 1 2 0 144 60 271 220 81 Normal
46 31 F 3 1 3 3 3000 4 3 1 2 3 1 2 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 0 160 55 401 340 85 Normal
47 48 F 3 1 2 3 1000 2 3 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 55 317 320 101 Normal
48 60 F 3 1 1 3 2000 2 2 2 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 148 42 283 235 83 Normal
49 50 F 3 1 2 2 2000 3 2 1 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 55 409 340 83 Normal
50 60 F 3 1 1 3 2000 2 3 2 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 148 50 283 250 88 Normal
51 40 F 3 1 1 2 2000 1 2 2 2 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 148 54 339 280 82 Normal
52 65 M 3 1 1 3 2000 4 2 3 1 1 2 0 0 1 2 2 15 50 50 2 0 0 2 2 1 1 1 1 1 2 1 3 1 1 2 1 2 1 0 155 52 375 130 35 Obstruction
53 38 F 3 1 1 3 3000 3 2 2 2 2 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 27 142 50 348 290 83 Normal
54 33 M 3 1 3 7 7000 6 3 3 2 1 2 0 0 2 1 1 20 5 13 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 164 52 478 520 108 Normal
55 65 M 3 1 1 2 1280 4 3 2 2 3 2 0 0 2 2 2 30 4 35 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 8 163 65 402 300 75 Obstruction
56 62 M 3 1 1 3 3000 3 2 1 2 3 2 0 0 2 1 2 20 18 42 2 0 0 2 1 2 2 0 0 0 0 1 1 1 2 2 2 2 2 15 163 58 409 210 51 Obstruction
57 60 m 3 1 1 3 2000 2 2 3 2 1 2 0 0 2 2 2 15 15 40 2 0 0 2 2 2 1 2 1 1 1 1 2 1 2 2 2 2 2 22 162 50 409 170 42 Obstruction
58 32 M 3 1 2 2 2000 4 1 1 2 2 2 0 0 2 1 3 25 6 7 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 22 159 56 464 430 93 Normal
59 35 M 3 1 2 7 2000 4 1 1 2 3 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 8 159 55 457 510 111 Normal
60 30 M 3 1 1 3 4000 4 2 1 2 2 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 1 0 148 58 431 420 97 Normal
61 65 M 4 1 1 2 2000 5 2 1 2 3 2 0 0 2 1 2 30 25 20 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 161 60 395 230 58 Obstruction
62 60 M 4 1 1 3 3000 4 3 3 2 4 2 0 0 2 2 2 15 5 45 2 0 0 2 1 1 1 1 1 1 1 1 3 1 1 2 1 1 2 22 158 50 396 180 45 Obstruction
63 70 M 4 1 1 3 6000 7 3 2 2 4 2 0 0 2 1 2 15 10 55 2 0 0 2 2 2 1 1 1 1 1 1 1 1 1 2 1 2 1 23 165 62 398 250 63 Obstruction
64 52 M 4 1 2 3 6000 5 3 2 1 4 2 0 0 1 2 2 22 24 30 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 31 164 60 435 340 78 Obstruction
65 60 M 4 1 2 2 2500 3 3 2 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 1 1 1 1 1 2 1 3 1 2 2 1 1 1 18 160 62 403 250 62 Obstruction
66 50 F 4 1 1 3 1000 2 2 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 1 2 1 1 1 0 153 52 327 170 52 Obstruction
67 45 F 4 1 3 3 2000 3 2 2 1 2 1 2 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 56 344 290 84 Normal
68 60 M 4 1 1 2 2000 5 3 2 2 1 2 0 0 2 2 2 15 4 45 2 0 0 2 2 1 1 2 1 1 1 1 3 1 2 2 1 2 2 0 160 52 403 100 25 Obstruction
69 35 F 4 1 2 7 750 2 1 1 2 3 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 23 112 29 244 200 82 Normal
70 38 F 4 1 1 3 2000 4 2 2 2 1 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 51 345 280 81 Normal
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71 30 M 4 1 3 2 5000 5 2 2 2 4 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 167 64 495 410 83 Normal
72 45 M 4 1 2 3 2000 4 3 2 2 3 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 60 441 450 102 Normal
73 42 M 4 1 1 2 300 3 3 2 2 3 2 0 0 2 3 0 0 0 0 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 157 51 435 250 57 Obstruction
74 60 M 4 1 1 2 750 2 3 2 2 4 2 0 0 2 3 0 0 0 0 2 0 0 2 1 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 171 55 440 300 68 Obstruction
75 40 M 4 1 1 1 1000 4 3 2 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 1 1 1 1 1 2 1 3 1 1 2 1 1 1 0 154 60 358 250 70 Obstruction
76 60 M 4 1 2 3 2000 6 3 2 2 4 2 0 0 2 2 3 20 4 40 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 166 62 423 440 104 Normal
77 50 F 4 1 2 3 750 2 3 2 2 3 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 19 146 58 305 310 101 Normal
78 65 M 4 1 2 3 1500 2 3 4 2 2 2 0 0 2 2 2 15 7 50 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 54 395 480 121 Normal
79 50 F 4 1 1 2 750 2 2 1 2 3 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 21 148 53 311 350 112 Normal
80 50 F 4 1 1 3 750 1 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 139 36 284 230 81 Normal
81 60 M 5 1 3 3 1000 3 2 4 2 3 2 0 0 2 2 2 20 4 40 2 0 0 2 2 2 1 2 1 1 2 1 3 1 2 2 1 1 2 0 157 61 393 290 74 Obstruction
82 75 M 5 1 2 3 1000 2 3 2 2 1 2 0 0 2 2 2 15 10 60 2 0 0 2 2 1 1 2 1 1 1 1 2 1 2 2 1 1 2 17 168 58 396 250 63 Obstruction
83 47 F 5 1 2 1 12000 4 2 2 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 1 1 2 0 0 0 0 1 3 1 1 2 1 1 2 23 140 75 295 170 58 Obstruction
84 35 F 5 1 2 1 3000 4 3 1 2 4 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 141 59 332 270 81 Normal
85 50 F 5 1 3 3 4000 8 3 4 1 4 2 0 0 1 3 0 0 0 0 1 3 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 155 65 409 350 85 Normal
86 43 M 5 1 3 2 5000 3 3 3 1 1 2 0 0 1 1 3 23 12 23 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 153 80 418 320 76 Obstruction
87 40 F 5 1 2 1 3000 5 2 2 2 1 1 1 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 9 144 70 327 300 92 Normal
88 32 F 5 1 4 7 3000 4 3 1 2 1 1 1 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 47 367 370 101 Normal
89 30 F 5 1 2 1 2000 4 2 1 2 1 1 1 1 2 3 0 0 0 0 2 0 0 2 2 1 2 0 0 0 0 1 1 1 1 2 1 1 1 0 139 70 340 280 82 Normal
90 40 F 5 1 1 1 2000 4 3 2 1 4 1 2 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 58 345 345 100 Normal
91 30 M 5 1 3 3 3000 4 3 2 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 153 80 448 520 116 Normal
92 35 F 5 1 2 1 3000 4 3 2 1 1 1 1 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 68 372 370 99 Normal
93 57 F 5 1 2 1 2000 4 2 1 2 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 139 61 264 350 132 Normal
94 32 F 5 1 3 1 2000 4 2 1 2 1 1 1 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 140 52 337 300 89 Normal
95 50 F 5 1 1 1 10000 6 3 4 1 4 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 0 145 70 302 320 106 Normal
96 33 F 5 1 3 1 2000 4 2 2 2 1 1 1 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 140 58 335 290 86 Normal
97 33 F 5 1 2 1 3000 3 2 1 2 1 1 1 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 143 55 344 300 87 Normal
98 43 F 5 1 2 1 10000 3 3 4 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 0 140 68 307 360 117 Normal
99 35 F 5 1 1 1 4000 6 2 2 2 4 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 138 70 323 360 111 Normal
100 45 F 5 1 4 1 3000 6 3 2 1 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 149 68 328 330 100 Normal
101 48 F 6 1 2 1 3000 2 3 2 1 4 1 2 1 2 3 0 0 0 0 1 1 1 2 2 1 2 0 0 0 0 1 2 1 2 2 2 1 1 0 141 70 296 310 104 Normal
102 38 F 6 1 2 2 2000 1 3 2 1 1 1 1 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 145 65 336 400 119 Normal
103 38 M 6 1 3 7 3000 4 3 2 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 82 457 400 87 Normal
104 45 F 6 2 3 1 5000 5 3 3 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 138 65 295 280 95 Normal
105 43 M 6 1 2 2 5000 6 2 2 2 3 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 49 411 480 116 Normal
106 32 M 6 2 3 2 3000 4 3 1 2 1 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 155 47 451 400 89 Normal
107 42 F 6 1 1 1 4000 4 2 1 2 3 1 2 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 151 70 342 290 85 Normal
108 42 M 6 2 1 3 3500 6 2 2 2 3 2 0 0 2 1 2 20 25 21 2 0 0 2 2 2 1 1 1 2 2 1 2 1 1 2 1 2 1 0 155 63 428 340 79 Obstruction
109 49 M 6 1 3 3 3000 3 3 3 1 1 2 0 0 1 2 1 20 9 19 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 21 145 72 378 400 105 Normal
110 51 M 6 1 2 3 2000 2 2 3 1 3 2 0 0 2 1 3 25 10 25 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 1 3 160 55 424 320 76 Obstruction
111 50 M 6 1 2 3 3000 3 1 1 2 1 2 0 0 2 1 3 20 7 30 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 15 151 70 395 300 76 Obstruction
112 52 M 6 1 3 3 6000 4 2 1 2 1 2 0 0 2 1 1 30 10 20 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 10 165 70 439 320 73 Obstruction
113 44 M 6 2 3 7 3000 5 2 2 2 1 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 8 153 75 416 400 96 Normal
114 40 F 6 1 1 1 3000 1 1 1 2 4 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 130 52 284 250 88 Normal
115 54 M 6 1 4 7 10000 6 3 4 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 68 400 480 120 Normal
116 43 F 6 1 3 1 12000 6 3 3 1 1 1 2 1 1 3 0 0 0 0 1 2 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 140 69 307 310 101 Normal
117 40 F 6 1 2 2 2000 5 2 1 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 57 345 330 96 Normal
118 30 F 6 1 4 1 7000 4 2 2 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 158 49 398 330 83 Normal
119 60 F 6 1 1 2 840 1 2 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 163 46 329 400 121 Normal
120 42 F 6 1 3 1 5000 5 2 2 2 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 1 2 1 1 1 0 145 62 324 240 74 Obstruction
121 55 F 7 1 1 3 840 1 1 1 2 3 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 3 1 1 2 1 1 1 0 151 52 306 210 69 Obstruction
122 55 F 7 1 1 1 8000 5 3 1 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 160 69 334 310 93 Normal
123 35 M 7 1 2 3 2000 4 1 1 2 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 152 59 434 450 104 Normal
124 30 M 7 1 3 2 5000 3 2 1 2 4 2 0 0 2 2 1 23 4 7 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 164 52 485 530 109 Normal
125 31 M 7 1 2 3 4000 3 3 3 1 2 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 166 68 490 460 94 Normal
126 30 M 7 1 2 4 8000 3 3 1 2 1 2 0 0 2 1 1 25 4 5 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 164 67 485 540 111 Normal
127 30 M 7 1 4 7 7000 3 2 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 7 170 82 506 600 118 Normal
128 48 M 7 1 1 7 2000 3 2 2 2 3 2 0 0 2 2 1 15 2 33 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 56 448 320 71 Obstruction
129 30 F 7 1 3 2 2000 4 2 1 2 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 14 144 54 355 420 118 Normal
130 37 F 7 1 1 3 4200 4 3 2 2 3 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 156 70 372 350 94 Normal
131 35 F 7 1 1 2 1500 3 3 2 2 3 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 150 54 359 320 89 Normal
132 35 F 7 1 2 1 6000 3 2 2 2 1 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 153 46 369 310 84 Normal
133 45 F 7 1 1 2 2000 2 2 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 54 344 360 105 Normal
134 60 F 7 1 1 1 2000 4 3 2 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 59 292 250 86 Normal
135 45 M 7 1 1 2 2000 5 2 1 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 44 404 440 109 Normal
136 40 F 7 1 1 3 2500 4 3 2 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 157 64 367 325 88 Normal
137 38 M 7 1 3 7 6000 5 3 2 2 2 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 153 58 430 490 114 Normal
138 49 M 7 1 3 7 4500 3 3 2 2 1 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 151 53 398 440 110 Normal
139 37 F 7 1 1 3 3000 3 2 2 2 3 1 2 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 61 347 300 86 Normal
140 35 M 7 1 3 7 5000 4 3 2 2 1 2 0 0 2 1 1 30 2 5 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 162 91 467 460 98 Normal
141 34 M 8 1 4 7 30000 3 3 3 1 1 2 0 0 2 1 1 30 5 5 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 6 154 64 442 490 111 Normal
142 35 M 8 1 3 7 6000 4 3 1 1 1 2 0 0 2 2 1 27 5 7 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 7 167 68 484 430 89 Normal
143 38 M 8 1 3 7 5000 4 2 1 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 167 75 477 410 86 Normal
144 55 M 8 1 2 3 5000 8 3 2 2 1 2 0 0 2 2 2 30 10 15 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 47 398 300 75 Obstruction
145 44 M 8 1 3 3 3500 4 2 1 1 1 2 0 0 2 1 1 20 3 24 2 0 0 2 2 2 1 2 1 2 2 2 0 0 0 0 0 2 2 15 160 60 440 460 104 Normal
146 45 M 8 1 3 7 25000 3 3 1 1 4 2 0 0 1 1 1 15 4 30 2 0 0 2 2 2 1 1 1 1 2 1 2 1 1 1 1 1 2 11 169 75 468 310 66 Obstruction
147 45 M 8 1 2 3 5000 4 3 2 2 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 1 2 2 2 2 8 160 66 438 310 71 Obstruction
148 39 M 8 1 3 3 5000 4 3 2 1 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 2 2 1 2 1 0 168 81 469 410 87 Normal
149 40 M 8 1 3 7 7000 3 3 2 1 1 2 0 0 2 3 0 0 0 0 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 1 0 170 70 483 480 99 Normal
150 55 F 8 1 2 3 5000 8 3 2 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 1 2 1 1 1 1 2 1 2 1 2 2 1 2 1 0 150 52 303 310 102 Normal
151 60 M 8 1 1 2 2000 4 2 1 2 1 2 0 0 2 2 2 15 22 25 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 45 386 300 78 Obstruction
152 42 F 8 1 4 7 25000 3 3 1 1 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 1 2 1 1 2 2 0 0 0 0 0 2 2 22 142 63 315 260 82 Normal
153 58 M 8 1 3 3 12000 11 3 4 1 1 2 0 0 1 2 3 15 22 23 2 0 0 2 2 2 1 1 1 2 2 1 1 1 2 2 2 1 2 0 163 78 418 320 76 Obstruction
154 57 M 8 1 4 3 5000 3 3 2 1 1 2 0 0 1 2 1 20 4 3 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 13 165 75 427 480 112 Normal
155 47 F 8 1 2 1 8000 8 3 2 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 11 163 78 365 310 85 Normal
156 35 F 8 1 2 3 3000 3 3 2 1 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 159 68 387 330 85 Normal
157 37 M 8 1 4 3 5000 5 3 3 1 1 2 0 0 1 3 0 0 0 0 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 174 73 503 520 103 Normal
158 32 M 8 1 3 7 6000 3 3 2 2 3 2 0 0 2 1 1 20 5 12 2 0 0 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 0 168 86 495 410 83 Normal
159 45 M 8 1 1 3 3000 2 3 1 2 3 2 0 0 2 1 2 30 1 15 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 1 7 172 45 478 370 77 Obstruction
160 42 F 8 1 5 7 25000 4 3 2 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 145 60 324 310 96 Normal
161 39 M 9 1 5 7 25000 3 3 2 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 85 469 530 113 Normal
162 35 F 9 1 3 2 5000 4 3 2 1 1 1 2 1 2 3 9 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 150 65 359 310 86 Normal
163 60 F 9 1 1 1 1500 2 3 2 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 145 52 274 250 91 Normal
164 37 F 9 1 2 3 4500 4 3 2 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 1 1 1 2 2 1 1 1 2 2 2 2 2 0 154 68 366 310 85 Normal
165 33 M 9 1 3 7 7000 4 2 2 2 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 170 56 499 490 98 Normal
166 55 F 9 1 2 3 5000 10 3 4 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 59 297 250 84 Normal
167 54 F 9 1 2 1 1000 2 2 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 149 61 303 285 94 Normal
168 37 M 9 1 2 3 2000 4 3 2 1 1 2 0 0 2 2 1 35 5 1 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 47 435 390 90 Normal
169 39 F 9 1 3 1 5000 4 3 3 2 1 1 3 1 2 3 0 0 0 0 1 3 2 2 2 2 1 1 1 2 2 1 1 2 2 2 2 1 1 11 154 54 361 360 100 Normal
170 57 F 9 1 3 1 10000 3 3 3 1 1 1 3 1 1 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 167 55 349 400 115 Normal
171 45 F 9 1 1 2 6000 5 3 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 149 52 328 300 91 Normal
172 40 F 9 1 1 2 2000 2 2 1 2 3 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 146 50 333 330 99 Normal
173 48 F 9 1 3 1 8000 4 3 4 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 1 0 157 61 345 380 110 Normal
174 50 F 9 1 1 2 1500 4 3 3 1 4 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 160 52 348 330 95 Normal
175 49 F 9 3 2 7 3000 2 2 2 1 4 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 2 1 2 2 1 2 0 156 60 339 330 97 Normal
176 42 F 9 1 1 1 3000 4 2 4 1 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 1 1 1 1 2 1 2 1 2 2 2 2 2 0 153 55 349 270 77 obstruction
177 43 F 9 1 2 2 2000 5 1 1 2 3 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 154 58 350 270 77 Obstruction
178 55 F 9 1 3 3 4000 5 3 4 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 52 306 270 88 Normal
179 40 F 9 1 1 2 2000 2 1 1 2 3 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 143 45 324 300 92 Normal
180 41 F 9 1 1 1 4000 4 3 2 1 4 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 56 336 300 89 Normal
181 57 F 10 1 1 1 2000 2 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 149 52 294 300 102 Normal
182 45 F 10 1 2 2 3000 2 1 1 2 2 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 149 57 328 270 82 Normal
183 31 F 10 1 2 1 10000 7 3 1 2 3 1 2 2 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 145 35 355 300 84 Normal
184 33 F 10 1 3 1 3000 4 2 2 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 149 55 362 300 83 Normal
185 45 F 10 1 1 2 3000 2 2 1 1 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 51 319 350 110 Normal
186 40 F 10 1 1 1 7000 3 3 1 1 2 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 156 60 364 360 99 Normal
187 60 F 10 1 1 2 1500 1 2 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 50 283 230 81 Normal
188 45 F 10 1 1 2 1500 3 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 152 50 338 300 89 Normal
189 55 F 10 1 3 1 5000 6 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 152 60 310 360 116 Normal
190 45 F 10 1 1 2 2000 2 1 1 2 1 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 154 62 344 340 99 Normal
191 39 F 10 1 2 2 5000 4 2 2 1 1 1 3 1 1 3 0 0 0 0 1 3 3 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 164 56 391 330 84 Normal
192 55 F 10 1 2 1 1000 1 2 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 167 54 355 380 107 Normal
193 40 M 10 1 3 7 20000 2 3 3 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 168 65 476 570 120 Normal
194 46 F 10 1 1 2 6000 8 1 2 2 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 153 60 338 290 86 Normal
195 30 F 10 3 3 2 4000 4 2 2 1 1 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 55 386 340 88 Normal
196 42 F 10 1 2 3 3000 2 2 1 2 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 149 54 336 300 89 Normal
197 50 F 10 1 3 1 5000 7 3 2 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 60 333 310 93 Normal
198 60 F 10 1 1 2 3000 5 3 3 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 0 155 50 305 250 82 Normal
199 60 F 10 1 1 1 5000 4 2 2 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 160 55 320 270 84 Normal
200 60 F 10 1 1 1 1000 1 2 2 1 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 63 335 300 89 Normal
201 58 F 11 1 3 1 20000 8 3 4 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 68 329 300 91 Normal
202 47 F 11 1 1 2 3500 4 3 3 1 1 1 3 2 2 3 0 0 0 0 1 0 0 2 2 2 1 1 1 2 2 1 1 2 2 2 2 2 2 0 164 60 368 320 87 Normal
203 50 F 11 1 1 2 1500 1 3 3 1 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 1 1 2 0 0 1 2 2 2 2 2 1 2 0 156 50 336 200 59 Obstruction
204 60 F 11 1 1 2 2000 3 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 146 50 277 250 90 Normal
205 36 F 11 1 2 1 4000 2 1 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 153 55 366 310 85 Normal
206 42 F 11 1 1 1 4000 3 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 1 2 2 0 154 62 352 290 82 Normal
207 50 F 11 1 1 2 2000 3 3 2 2 1 1 3 1 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 60 333 320 96 Normal
208 53 M 11 1 1 7 15000 2 3 3 1 1 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 172 63 460 400 87 Normal
209 57 M 11 1 3 7 10000 6 3 2 1 3 2 0 0 2 1 2 18 10 40 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 157 60 400 310 77 obstruction
210 41 M 11 1 4 7 15000 3 3 2 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 14 165 75 464 650 140 Normal
211 35 M 11 1 2 3 4000 4 2 1 2 3 2 0 0 2 1 1 25 5 10 2 0 0 2 2 2 2 0 0 0 0 1 1 1 1 2 2 2 2 0 168 65 414 400 97 Normal
212 38 M 11 1 3 3 2000 4 3 2 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 165 100 471 530 112 Normal
213 32 M 11 1 3 7 5000 4 3 2 1 1 2 0 0 2 1 4 20 3 12 2 0 0 2 2 2 2 0 0 0 0 1 1 1 1 2 2 2 2 0 160 62 468 500 107 Normal
214 60 M 11 1 2 3 2000 3 2 1 2 3 2 0 0 2 1 2 20 25 40 2 0 0 2 2 2 1 1 1 1 1 1 1 1 1 2 2 2 2 11 162 45 409 300 73 Obstruction
215 32 M 11 1 3 7 4000 4 3 2 2 3 2 0 0 2 1 3 17 5 15 2 0 0 2 2 2 2 0 0 0 0 1 3 1 2 2 2 2 2 29 169 90 498 450 90 Normal
216 30 M 11 1 3 3 2000 2 2 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 6 142 35 428 400 93 Normal
217 41 M 11 1 3 3 2000 5 3 2 1 1 2 0 0 1 1 2 20 8 21 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 166 61 467 420 90 Normal
218 42 M 11 1 3 7 2000 5 2 4 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 176 62 499 550 110 Normal
219 55 F 11 1 2 3 4000 7 3 3 1 1 1 3 1 1 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 0 152 53 310 300 97 Normal
220 39 F 11 1 2 2 2000 5 1 1 1 2 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 2 2 2 1 2 0 149 44 345 340 98 Normal
221 45 F 12 1 2 3 4000 3 3 3 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 70 377 330 87 Normal
222 58 F 12 1 1 2 1500 1 2 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 50 289 250 86 Normal
223 50 F 12 1 1 1 1000 5 2 2 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 149 48 314 265 84 Normal
224 43 F 12 1 1 1 800 3 2 2 2 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 145 73 322 340 105 Normal
225 60 F 12 2 3 1 4000 4 2 2 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 0 144 61 271 270 100 Normal
226 31 F 12 1 3 1 2000 4 2 2 1 1 1 2 1 1 3 0 0 0 0 1 2 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 55 364 320 88 Normal
227 36 F 12 1 3 1 3000 4 2 2 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 153 52 366 350 96 Normal
228 45 F 12 3 1 1 2500 3 2 3 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 2 2 2 2 1 0 141 46 304 200 66 obstruction
229 54 M 12 2 3 2 3000 6 2 1 2 3 2 0 0 2 1 2 30 5 24 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 158 50 410 400 97 Normal
230 37 M 12 1 2 2 1000 2 2 2 2 1 2 0 0 2 2 2 20 22 16 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 15 158 54 449 320 71 Obstruction
231 45 F 12 1 1 1 4000 4 2 4 1 3 1 3 2 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 13 140 44 301 290 96 Normal
232 43 M 12 1 3 2 1000 1 2 2 2 3 2 0 0 2 2 1 20 1 13 2 0 0 2 2 2 2 0 0 0 0 1 3 1 2 2 2 2 2 0 151 53 411 310 75 Obstruction
233 30 F 12 1 3 1 2000 4 1 1 2 3 1 2 2 2 3 0 0 0 0 1 1 1 2 2 2 1 2 2 2 2 1 3 1 1 2 2 1 2 11 148 37 367 320 87 Normal
234 60 M 12 1 1 3 2000 4 1 1 2 3 2 0 0 2 2 2 30 22 27 2 0 0 2 2 2 1 1 1 1 1 1 3 1 1 2 2 2 2 0 149 51 286 140 49 Obstruction
235 40 F 12 1 1 3 1000 5 1 1 2 3 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 25 149 63 342 290 85 Normal
236 65 F 12 2 1 1 5000 5 1 1 2 3 1 3 2 2 3 0 0 0 0 1 4 1 2 2 2 2 1 2 0 0 1 1 1 2 2 2 2 1 0 150 70 275 350 127 Normal
237 50 F 12 1 2 1 2000 3 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 150 76 317 310 98 Normal
238 42 M 12 1 4 7 25000 4 3 2 1 1 2 0 0 1 3 0 0 0 0 1 3 2 2 1 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 180 60 512 460 90 Normal
239 31 M 12 1 6 7 10000 4 3 3 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 72 487 510 105 Normal
240 55 F 12 2 3 7 10000 4 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 147 62 294 250 85 Normal
241 54 F 13 1 3 1 4000 4 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 55 322 300 93 Normal
242 36 F 13 1 2 3 2000 2 2 2 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 60 359 390 109 Normal
243 70 F 13 1 1 3 4000 5 3 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 1 1 1 2 2 1 3 1 2 2 2 2 2 0 147 52 252 250 99 Normal
244 40 M 13 1 2 3 1000 4 2 1 2 3 2 0 0 2 2 2 20 4 15 2 0 0 2 2 2 2 0 0 0 0 1 1 1 1 2 2 2 2 0 159 48 445 310 70 Obstruction
245 50 M 13 1 3 3 1000 4 3 2 2 4 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 1 2 11 167 60 449 400 89 Normal
246 54 F 13 1 3 1 4000 8 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 48 352 290 82 Normal
247 50 M 13 1 1 2 4000 5 1 1 2 3 2 0 0 2 1 2 20 10 30 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 152 58 399 350 88 Normal
248 60 M 13 1 2 3 2000 1 1 1 2 3 2 0 0 2 2 2 20 25 10 2 0 0 2 2 2 1 1 1 1 2 1 3 1 1 2 1 2 2 13 150 54 369 290 78 Obstruction
249 55 M 13 1 2 3 1000 6 2 1 2 3 2 0 0 2 1 2 20 25 35 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 23 165 55 432 340 79 Obstruction
250 65 M 13 1 1 2 1000 2 1 1 2 3 2 0 0 2 2 2 20 5 25 2 0 0 2 2 2 2 0 0 0 0 1 1 1 1 2 1 2 2 18 159 43 288 250 87 Normal
251 50 M 13 1 2 2 1000 3 1 1 2 3 2 0 0 2 1 2 20 25 30 2 0 0 2 2 2 1 2 1 1 1 1 3 1 1 2 1 2 2 19 157 44 416 200 48 Obstruction
252 75 M 13 1 2 7 2000 2 1 1 2 4 2 0 0 2 1 2 25 4 50 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 22 159 50 365 320 88 Normal
253 56 M 13 1 1 3 1500 6 1 2 2 3 2 0 0 2 1 2 30 5 25 2 0 0 2 2 2 1 1 1 1 1 1 1 1 1 2 1 1 1 21 170 53 447 350 78 Obstruction
254 60 M 13 1 3 2 4000 6 3 1 2 3 2 0 0 2 1 2 20 10 40 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 22 170 49 437 320 73 Obstruction
255 32 F 13 1 2 7 3000 4 1 1 2 3 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 21 150 46 367 300 82 Normal
256 38 M 13 1 3 7 5000 6 2 2 2 3 2 0 0 2 1 2 28 10 10 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 169 44 484 350 72 Obstruction
257 57 M 13 1 1 2 2000 3 3 1 2 3 2 0 0 2 2 2 22 10 5 2 0 0 2 2 2 1 2 1 1 2 2 0 0 0 0 0 2 2 8 160 50 410 150 36 Obstruction
258 65 M 13 1 2 2 4000 8 1 2 2 3 2 0 0 2 1 2 40 22 25 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 12 164 38 405 350 86 Normal
259 30 F 13 1 3 1 5000 4 3 4 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 22 150 39 373 340 91 Normal
260 41 F 13 1 3 1 4000 4 3 1 2 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 40 330 290 88 Normal
261 45 F 14 1 2 3 3000 2 2 1 2 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 141 50 304 270 89 Normal
262 55 F 14 1 1 2 2000 1 3 2 1 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 56 285 260 91 Normal
263 47 F 14 1 3 1 3000 4 3 3 1 4 2 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 65 307 290 94 Normal
264 56 F 14 1 3 1 12000 3 2 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 138 65 264 300 114 Normal
265 35 F 14 1 2 1 4000 5 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 56 341 300 88 Normal
266 38 F 14 1 4 7 15000 4 3 4 1 1 1 2 1 1 3 0 0 0 0 1 1 1 2 2 2 1 1 1 1 1 1 3 1 2 1 1 1 1 0 153 60 361 330 91 Normal
267 55 F 14 1 2 7 3000 2 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 2 1 2 0 154 59 316 260 82 Normal
268 42 F 14 1 3 7 5000 5 3 2 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 154 58 352 300 85 Normal
269 38 F 14 1 3 2 1000 4 2 2 2 1 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 1 0 158 57 376 260 69 Obstruction
270 40 F 14 1 2 2 1000 8 3 4 1 1 1 3 2 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 1 2 2 1 2 1 0 147 51 336 240 71 Obstruction
271 42 F 14 1 3 2 1000 5 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 157 58 361 340 94 Normal
272 40 F 14 1 2 2 1000 5 3 2 1 3 1 3 2 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 50 361 280 77 Obstruction
273 35 F 14 1 2 2 1000 5 3 2 1 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 45 359 310 86 Normal
274 45 F 14 1 2 2 1000 5 2 2 2 3 2 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 1 0 146 40 319 240 75 Obstruction
275 48 M 14 1 3 2 1000 7 2 2 2 3 2 0 0 2 2 3 25 10 17 2 0 0 2 1 2 1 2 1 1 1 1 3 1 2 2 2 2 2 0 168 62 458 310 68 Obstruction
276 65 F 14 1 1 1 1000 3 3 2 2 5 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 157 47 297 330 111 Normal
277 55 F 14 1 1 2 1000 3 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 32 285 250 88 Normal
278 54 F 14 1 2 1 3000 5 3 2 1 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 56 319 360 113 Normal
279 55 F 14 1 2 2 1000 2 3 1 2 3 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 0 140 48 273 290 106 Normal
280 50 F 14 1 2 2 1000 3 2 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 156 63 336 280 83 Normal
281 50 M 15 1 3 2 1000 4 2 1 2 3 1 3 2 2 2 3 45 10 5 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 1 2 1 0 160 60 426 330 77 Obstruction
282 62 F 15 1 2 1 1000 1 2 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 2 2 1 1 1 15 149 51 280 290 103 Normal
283 60 M 15 1 2 2 1000 2 1 1 2 3 2 0 0 2 2 2 30 12 20 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 156 40 389 350 90 Normal
284 45 M 15 1 2 2 1000 4 2 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 19 163 28 448 520 116 Normal
285 35 M 15 1 3 2 1000 4 3 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 169 53 491 500 102 Normal
286 60 M 15 1 2 2 1000 3 1 1 2 3 2 0 0 2 2 2 20 16 25 2 0 0 2 2 2 1 2 1 2 2 1 1 2 2 2 1 1 1 0 159 55 399 300 75 Obstruction
287 49 M 15 1 3 2 1500 4 3 2 1 1 2 0 0 1 2 2 20 10 19 2 0 0 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 22 168 70 456 490 107 Normal
288 45 F 15 1 2 2 1500 7 2 2 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 11 153 50 341 350 103 Normal
289 70 F 15 1 1 2 1000 1 2 2 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 48 274 200 73 Obstruction
290 55 F 15 1 2 1 1500 4 3 3 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 2 2 1 1 1 0 149 55 300 160 53 Obstruction
291 42 F 15 1 2 2 1500 2 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 157 60 342 260 76 Obstruction
292 32 F 15 1 3 2 2000 4 3 2 2 3 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 1 2 1 2 1 1 2 1 2 2 1 1 1 0 151 62 370 360 97 Normal
293 32 F 15 1 3 2 2500 3 2 4 1 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 153 56 377 350 93 Normal
294 42 M 15 1 2 2 1500 4 1 1 2 3 2 0 0 2 2 2 25 3 15 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 168 45 472 450 95 Normal
295 35 F 15 1 3 2 5000 5 3 4 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 11 155 55 375 360 96 Normal
296 52 F 15 1 1 2 1500 4 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 145 49 296 330 111 Normal
297 60 F 15 1 1 2 3000 5 3 2 1 3 1 3 2 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 2 2 2 2 2 0 140 37 259 240 93 Normal
298 55 F 15 1 1 2 1500 5 1 1 2 3 1 3 2 2 3 0 0 0 0 1 4 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 145 45 288 250 87 Normal
299 55 F 15 1 2 2 4500 6 2 2 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 1 1 0 153 40 313 200 64 Obstruction
300 45 F 15 1 1 2 3500 4 2 4 1 3 1 3 2 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 157 55 334 290 87 Normal
301 45 F 16 1 1 2 3000 2 3 3 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 44 319 290 91 Normal
302 32 F 16 1 3 2 2500 3 3 2 2 3 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 2 2 2 1 2 0 155 55 383 320 83 Normal
303 45 F 16 1 1 2 7000 5 3 4 1 3 1 3 2 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 160 54 362 400 110 Normal
304 45 F 16 1 1 2 3500 4 2 2 1 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 150 49 331 340 103 Normal
305 37 F 16 1 2 2 2000 5 2 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 40 353 320 91 Normal
306 36 M 16 1 4 3 5000 6 2 3 2 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 174 64 506 500 99 Normal
307 31 F 16 1 3 1 3500 6 2 3 2 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 1 2 1 1 1 1 1 2 2 2 2 1 1 0 161 62 404 300 74 Obstruction
308 49 M 16 1 4 7 15000 5 3 4 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 1 2 2 1 1 1 0 166 67 449 420 93 Normal
309 44 F 16 1 4 7 20000 5 3 4 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 1 1 1 0 156 67 353 360 102 Normal
310 45 M 16 1 3 7 3000 5 3 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 1 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 163 62 448 530 118 Normal
311 53 F 16 1 1 3 20000 3 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 1 2 2 2 2 0 152 62 316 290 92 Normal
312 31 F 16 1 1 3 4000 5 3 2 2 3 1 3 1 2 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 0 152 67 377 280 74 Obstruction
313 45 F 16 1 1 7 4000 3 2 2 2 3 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 152 52 338 290 86 Normal
314 45 F 16 1 1 1 3000 3 3 2 2 3 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 1 0 159 55 359 300 83 Normal
315 50 F 16 1 1 2 6000 10 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 146 53 305 340 111 Normal
316 50 F 16 1 2 1 4000 6 1 1 2 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 0 152 52 324 240 74 Obstruction
317 36 M 16 1 3 7 15000 4 2 2 2 1 2 0 0 1 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 169 69 489 560 114 Normal
318 56 M 16 1 1 2 7000 7 1 1 2 3 2 0 0 2 1 2 18 30 38 2 0 0 2 2 2 1 2 1 1 1 1 1 1 1 2 2 2 2 0 164 52 426 470 110 Normal
319 33 M 16 1 2 2 4000 5 3 1 2 3 2 0 0 2 1 4 28 3 5 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 17 165 53 482 430 89 Normal
320 55 M 16 1 1 3 4000 3 2 2 2 3 2 0 0 2 1 2 20 25 35 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 11 153 43 391 300 77 Obstruction
321 60 M 17 1 1 2 2000 2 3 2 2 3 2 0 0 2 1 2 20 10 40 2 0 0 2 2 2 1 2 1 1 1 1 1 1 2 2 2 2 2 18 151 37 372 270 72 Obstruction
322 45 F 17 1 1 2 3000 5 2 2 2 3 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 21 156 54 350 340 97 Normal
323 65 M 17 1 1 7 2000 2 3 2 2 3 2 0 0 2 1 2 20 3 45 2 0 0 2 2 2 1 2 1 1 1 1 1 1 1 2 2 2 2 0 153 36 368 150 41 Obstruction
324 42 M 17 1 2 7 10000 2 3 1 1 1 2 0 0 2 3 0 0 0 0 1 4 1 2 2 2 1 2 1 1 1 1 3 1 2 2 2 2 2 0 159 76 441 390 88 Normal
325 42 M 17 1 1 3 4000 6 3 2 2 3 2 0 0 2 1 2 15 25 27 2 0 0 2 2 2 2 0 0 0 0 1 1 1 1 2 2 2 2 0 157 41 435 370 85 Normal
326 65 F 17 1 3 3 2000 4 1 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 14 166 57 324 400 123 Normal
327 30 M 17 1 3 7 3000 5 3 2 2 3 2 0 0 2 3 0 0 0 0 1 3 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 37 441 400 91 Normal
328 48 F 17 1 1 2 7000 6 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 42 326 380 117 Normal
329 58 M 17 1 3 3 3000 3 3 4 1 1 2 0 0 1 1 1 17 10 41 2 0 0 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 0 174 63 455 450 99 Normal
330 50 M 17 1 1 2 5000 6 3 2 2 3 2 0 0 2 2 2 20 22 20 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 17 166 56 446 490 110 Normal
331 50 M 17 1 3 2 6000 5 2 1 1 3 2 0 0 2 1 2 20 3 30 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 17 165 40 443 310 70 Obstruction
332 54 M 17 1 1 3 5000 5 3 2 2 3 2 0 0 2 1 2 20 6 34 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 12 173 54 461 510 110 Normal
333 30 M 17 1 1 2 8000 3 3 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 15 162 55 478 440 92 Normal
334 52 F 17 1 1 1 6000 8 3 3 1 1 1 3 1 2 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 150 72 311 300 96 Normal
335 30 F 17 1 1 2 5000 7 3 2 2 3 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 138 28 337 270 80 Normal
336 45 F 17 1 1 2 4000 6 3 2 1 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 156 54 350 280 80 Normal
337 40 F 17 1 1 2 4000 4 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 1 2 2 2 2 2 0 153 58 355 360 101 Normal
338 60 F 17 1 1 1 10000 9 3 2 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 142 34 265 250 94 Normal
339 32 F 17 1 3 2 8000 9 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 141 64 340 320 94 Normal
340 55 F 17 1 1 1 4000 6 1 3 2 3 2 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 33 285 250 88 Normal
341 50 F 18 1 1 1 5000 5 2 1 2 3 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 72 351 310 83 Normal
342 38 F 18 1 1 1 5000 5 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 1 0 159 71 379 420 110 Normal
343 45 F 18 1 1 2 6000 6 2 2 2 3 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 1 0 149 57 328 180 55 Obstruction
344 55 F 18 1 1 2 3000 5 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 142 44 279 310 111 Normal
345 55 F 18 1 1 3 3000 7 3 2 2 3 2 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 0 149 41 300 280 93 Normal
346 30 F 18 1 1 2 10000 5 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 38 361 370 102 Normal
347 60 F 18 1 2 1 4000 3 3 2 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 147 39 280 160 57 Obstruction
348 50 F 18 1 3 7 10000 2 3 1 2 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 56 333 270 82 Normal
349 51 F 18 1 2 7 1500 2 3 2 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 53 308 370 120 Normal
350 60 F 18 1 1 3 4000 5 3 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 41 292 250 86 Normal
351 60 F 18 1 1 2 2000 1 1 1 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 1 2 2 2 2 0 149 54 286 276 94 Normal
352 38 F 18 1 2 2 3000 4 3 2 2 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 43 367 310 84 Normal
353 30 F 18 1 1 3 5000 5 3 2 1 3 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 153 37 383 410 107 Normal
354 30 F 18 1 5 1 24000 6 2 2 1 1 1 1 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 84 407 350 86 Normal
355 50 F 18 1 3 2 3000 2 2 1 1 2 1 3 2 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 145 47 302 260 86 Normal
356 60 F 18 1 3 7 3000 4 3 2 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 142 50 265 300 113 Normal
357 46 F 18 1 2 1 8000 7 3 2 1 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 1 0 146 59 316 240 76 Obstruction
358 40 F 18 1 2 1 3000 4 3 2 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 55 348 350 101 Normal
359 30 F 18 1 3 1 20000 15 3 4 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 41 376 310 82 Normal
360 33 F 18 1 3 1 5000 4 2 2 2 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 1 2 2 2 1 0 167 60 417 350 84 Normal
361 57 M 19 1 3 3 5000 4 2 2 2 1 2 0 0 2 1 4 25 10 32 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 172 69 450 400 89 Normal
362 50 F 19 1 1 2 3000 4 3 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 17 157 49 339 300 88 Normal
363 40 M 19 1 3 3 3000 6 2 1 2 1 2 0 0 2 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 169 70 479 500 104 Normal
364 53 F 19 1 3 1 3000 5 3 1 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 48 297 310 104 Normal
365 60 F 19 1 1 1 1000 2 2 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 152 48 296 250 84 Normal
366 37 F 19 1 2 7 3000 2 3 1 2 2 1 3 1 2 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 149 57 350 300 86 Normal
367 52 F 19 1 3 1 3000 3 3 2 2 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 150 50 311 380 122 Normal
368 31 F 19 1 3 1 10000 9 3 4 1 1 1 1 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 164 65 413 460 111 Normal
369 55 F 19 1 1 1 5000 3 3 3 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 55 285 340 119 Normal
370 50 F 19 1 1 1 3000 2 1 1 2 3 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 44 317 250 79 Obstruction
371 36 M 19 1 3 7 7000 4 3 2 1 4 2 0 0 2 3 0 0 0 0 1 0 0 2 2 2 2 0 0 0 0 1 3 1 2 2 1 1 1 0 172 70 499 450 90 Normal
372 45 F 19 1 3 1 5000 4 2 3 1 1 1 3 1 1 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 166 75 380 330 87 Normal
373 50 F 19 1 3 7 15000 6 3 4 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 156 70 336 390 116 Normal
374 30 F 19 1 2 2 5000 5 3 2 2 3 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 163 44 413 350 85 Normal
375 35 F 19 1 1 2 4000 5 3 2 1 2 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 55 359 300 84 Normal
376 31 F 19 1 3 1 2000 4 3 1 2 1 1 2 3 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 162 64 407 350 86 Normal
377 35 F 19 1 2 2 1000 4 3 2 2 2 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 52 341 260 76 Obstruction
378 45 F 19 1 2 1 5000 4 2 2 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 2 2 2 1 1 0 152 66 338 390 115 Normal
379 39 F 19 1 3 1 3000 2 3 3 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 85 364 410 113 Normal
380 46 F 19 1 3 1 10000 3 3 3 1 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 3 1 1 2 1 2 1 0 151 104 331 330 100 Normal
381 41 M 20 1 2 7 3000 2 3 3 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 150 65 413 440 106 Normal
382 34 M 20 1 3 2 4000 4 2 2 1 1 2 0 0 1 3 0 0 0 0 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 1 0 166 60 483 420 87 Normal
383 46 M 20 1 3 5 5000 4 2 2 2 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 64 439 440 100 Normal
384 55 F 20 1 1 1 5000 6 3 4 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 149 50 300 265 88 Normal
385 51 F 20 1 1 1 5000 5 3 1 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 50 327 340 104 Normal
386 30 F 20 1 3 1 11000 6 3 2 1 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 160 85 404 400 99 Normal
387 44 F 20 3 1 7 5000 4 2 2 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 147 55 326 360 110 Normal
388 34 F 20 2 3 1 15000 4 2 1 1 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 153 52 372 360 97 Normal
389 39 F 20 1 3 7 8000 2 2 2 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 53 330 330 100 Normal
390 55 F 20 1 1 1 8000 9 3 3 1 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 144 55 285 320 112 Normal
391 33 F 20 1 3 1 6000 4 3 2 1 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 154 65 378 340 90 Normal
392 39 F 20 1 3 1 6000 5 2 2 1 1 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 3 1 2 2 1 1 1 0 145 55 333 260 78 Obstruction
393 49 F 20 1 2 1 5500 2 3 2 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 148 63 314 310 99 Normal
394 38 F 20 1 2 1 20000 5 3 1 2 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 147 70 342 350 102 Normal
395 33 F 20 1 3 1 15000 4 3 2 1 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 70 353 320 91 Normal
396 46 F 20 1 3 1 4000 4 3 2 1 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 0 144 85 310 250 81 Normal
397 37 F 20 1 3 1 6000 4 2 3 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 160 95 384 340 88 Normal
398 38 F 20 2 3 7 5000 6 2 3 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 152 55 358 310 86 Normal
399 31 M 20 1 3 3 5000 4 2 1 2 4 2 0 0 2 1 2 16 25 15 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 60 487 400 82 Normal
400 46 M 20 1 3 7 7000 7 2 3 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 13 168 70 463 430 93 Normal
401 50 F 21 1 1 7 5000 5 2 2 1 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 1 0 153 70 327 310 95 Normal
402 35 F 21 1 2 1 3000 4 2 1 2 1 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 156 55 378 320 85 Normal
403 40 F 21 1 1 2 4000 6 1 1 2 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 0 154 62 358 300 84 Normal
404 45 M 21 1 2 2 10000 4 1 1 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 51 441 450 102 Normal
405 40 M 21 3 2 7 5000 5 2 2 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 85 452 490 108 Normal
406 48 F 21 1 3 2 5000 5 1 2 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 50 317 300 95 Normal
407 35 F 21 1 2 2 4000 5 1 2 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 148 42 353 300 85 Normal
408 58 M 21 2 3 7 5000 2 1 2 2 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 158 52 401 360 90 Normal
409 60 F 21 1 1 2 3000 7 2 2 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 2 1 2 2 1 1 1 0 152 49 296 300 101 Normal
410 55 F 21 3 1 1 5000 6 2 2 1 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 154 70 316 360 114 Normal
411 40 F 21 1 3 1 4000 4 2 2 2 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 156 90 364 320 88 Normal
412 31 F 21 1 3 1 5000 4 3 2 1 1 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 59 358 320 89 Normal
413 45 F 21 3 3 1 3000 5 1 1 2 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 136 36 289 310 107 Normal
414 37 F 21 1 1 1 5000 5 1 1 2 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 64 369 360 97 Normal
415 45 M 21 1 1 2 4000 4 1 2 2 3 2 0 0 2 1 2 30 25 15 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 160 53 438 470 107 Normal
416 45 M 21 1 3 7 6000 4 2 2 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 13 165 67 455 500 110 Normal
417 35 F 21 1 1 2 750 2 2 1 2 3 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 0 155 53 375 320 85 Normal
418 50 M 21 1 1 2 4750 2 3 2 2 4 2 0 0 2 3 0 0 0 0 2 0 0 2 1 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 161 64 429 520 121 Normal
419 55 M 21 1 3 7 5000 6 2 2 2 3 2 0 0 2 1 2 25 10 30 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 2 2 2 0 168 65 442 300 68 Obstruction
420 47 F 21 1 3 1 20000 15 3 4 1 1 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 17 157 52 347 300 86 Normal
421 40 M 22 3 2 3 2000 1 1 1 2 3 2 0 0 2 2 2 20 25 10 2 0 0 2 2 2 1 1 1 1 2 1 3 1 1 2 1 2 2 0 156 67 435 310 71 Obstruction
422 48 M 22 1 4 7 10,000 6 3 4 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 163 75 441 510 116 Normal
423 39 M 22 2 3 7 10000 6 3 2 1 3 2 0 0 2 1 2 18 10 21 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 158 63 445 450 101 Normal
424 42 F 22 1 1 3 4000 5 3 2 2 3 1 3 1 2 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 1 2 1 2 2 2 2 2 8 146 59 327 370 113 Normal
425 35 F 22 1 1 7 4000 3 2 2 2 3 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 2 0 160 55 390 350 90 Normal
426 56 F 22 1 1 1 3000 3 3 2 2 3 1 3 2 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 1 0 138 45 264 220 83 Normal
427 32 F 22 1 3 1 3000 5 3 1 1 1 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 153 56 377 350 93 Normal
428 46 F 22 1 1 1 1000 2 2 2 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 158 61 353 370 105 Normal
429 51 F 22 1 2 7 3000 2 3 1 2 2 1 3 1 2 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 163 57 354 320 90 Normal
430 59 F 22 1 3 1 3000 3 3 2 2 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 149 45 289 350 121 Normal
431 39 F 22 1 3 1 10000 9 3 4 1 1 1 1 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 155 59 364 340 93 Normal
432 42 F 22 1 1 1 5000 3 3 3 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 145 52 324 400 123 Normal
433 55 F 22 1 1 1 3000 2 1 1 2 3 1 3 1 2 3 0 0 0 0 1 1 3 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 60 349 290 83 Normal
434 33 M 22 1 1 7 2000 2 3 2 2 3 2 0 0 2 1 2 20 3 13 2 0 0 2 2 2 1 2 1 1 1 1 1 1 1 2 2 2 2 0 170 68 499 550 110 Normal
435 57 M 22 1 2 2 1500 4 1 1 2 3 2 0 0 2 2 2 25 3 15 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 153 55 386 270 70 Obstruction
436 43 M 22 1 3 7 20000 2 3 3 1 1 2 0 0 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 15 170 69 476 520 109 Normal
437 36 M 22 2 3 7 15000 4 2 2 2 1 2 0 0 1 3 0 0 0 0 1 3 2 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 169 73 489 450 92 Normal
438 45 M 22 1 2 2 1000 3 1 1 2 3 2 0 0 2 2 2 20 15 22 2 0 0 2 2 2 1 2 1 2 2 1 1 2 2 2 1 1 1 0 154 60 417 500 120 Normal
439 36 F 22 1 1 2 1500 4 3 3 1 4 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 7 165 59 402 350 87 Normal
440 45 F 22 3 2 7 3000 2 2 2 1 4 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 2 1 2 2 1 2 0 152 56 338 320 95 Normal
441 58 F 23 1 1 1 3000 4 2 4 1 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 1 1 1 1 2 1 2 1 2 2 2 2 2 0 157 60 317 370 117 Normal
442 51 F 23 1 2 2 2000 5 1 1 2 3 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 148 52 308 250 81 Normal
443 44 F 23 1 1 2 1500 4 3 3 1 4 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 146 55 322 350 109 Normal
444 55 F 23 3 2 7 3000 2 2 2 1 4 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 1 2 1 2 2 1 2 0 159 56 331 300 91 Normal
445 52 F 23 1 1 1 3000 4 2 4 1 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 1 1 1 1 2 1 2 1 2 2 2 2 2 0 168 62 366 400 109 Normal
446 48 F 23 1 2 2 2000 5 1 1 2 3 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 1 2 2 2 2 2 2 2 0 144 52 305 250 82 Normal
447 60 M 23 1 2 3 4000 8 3 1 2 3 2 0 0 2 1 1 25 4 35 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 163 45 413 350 85 Normal
448 65 M 23 1 3 1 6000 7 3 3 1 1 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 1 19 148 67 269 150 56 Obstruction
449 65 F 23 1 1 1 2000 2 1 1 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 1 1 1 1 1 1 1 4 1 1 2 1 2 1 0 153 51 285 228 80 Normal
450 35 F 23 1 2 2 3000 5 3 2 1 2 1 1 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 3 1 1 2 2 2 1 0 152 53 366 330 90 Normal
451 62 M 23 1 2 2 4500 5 2 1 2 3 2 0 0 2 2 2 15 30 44 2 0 0 2 2 1 1 1 1 1 1 1 3 1 1 1 1 2 2 0 163 46 409 140 34 Obstruction
452 35 F 23 1 2 3 4000 4 3 3 1 1 1 1 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 30 141 38 332 270 81 Normal
453 56 F 23 1 3 7 14000 7 3 3 1 4 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 153 54 310 250 81 Normal
454 65 F 23 1 2 1 5000 6 2 2 2 1 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 147 46 266 280 105 Normal
455 65 F 23 1 1 1 1000 1 2 1 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 145 37 260 250 96 Normal
456 30 F 23 1 4 1 4000 5 3 4 1 1 1 1 2 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 1 1 1 1 0 153 58 382 370 97 Normal
457 55 F 23 1 3 2 5000 3 3 2 2 3 1 3 1 2 3 0 0 0 0 1 1 1 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 140 49 273 380 139 Normal
458 38 M 23 1 1 2 2500 4 2 2 1 3 2 0 0 2 3 0 0 0 0 2 0 0 2 1 2 2 0 0 0 0 1 1 2 2 2 1 1 1 0 155 79 437 293 67 Obstruction
459 45 F 23 1 2 3 3000 5 2 2 2 1 1 3 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 133 33 280 290 103 Normal
460 38 F 23 1 3 2 3000 4 3 4 1 4 1 2 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 147 36 342 290 85 Normal
461 42 F 24 1 3 3 3000 3 3 4 1 4 1 2 1 1 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 151 57 346 442 128 Normal
462 34 M 24 1 3 2 10000 7 2 4 1 3 2 0 0 2 3 0 0 0 0 2 0 0 2 1 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 175 61 513 530 103 Normal
463 55 F 24 1 2 1 3000 5 2 3 1 4 1 3 1 1 3 0 0 0 0 2 0 0 2 1 2 2 0 0 0 0 1 2 2 2 2 1 2 1 0 148 49 297 304 102 Normal
464 32 M 24 1 3 3 6000 8 3 4 1 4 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 170 72 508 650 128 Normal
465 35 M 24 1 4 7 5000 5 3 4 1 1 2 0 0 2 2 1 15 5 18 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 175 70 511 650 127 Normal
466 60 F 24 1 1 2 2000 5 2 1 2 3 1 3 1 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 11 139 53 256 520 203 Normal
467 45 M 24 1 3 6 8000 7 3 3 1 4 2 0 0 2 3 0 0 0 0 1 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 1 2 0 172 70 478 570 119 Normal
468 40 F 24 1 1 7 6000 4 3 2 1 3 1 3 2 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 1 2 2 1 2 0 146 42 333 295 88 Normal
469 30 M 24 1 2 3 3000 3 1 1 2 3 2 0 0 2 1 1 20 2 10 2 0 0 2 2 2 2 0 0 0 0 2 0 0 0 0 0 2 2 0 165 55 489 650 133 Normal
470 33 M 24 1 1 3 5000 3 1 1 2 3 2 0 0 2 3 0 0 0 0 2 0 0 2 2 2 2 0 0 0 0 1 1 2 2 2 1 2 2 11 160 67 465 314 67 Obstruction
471 35 M 24 1 1 1 36000 4 1 3 1 3 2 0 0 1 3 0 0 0 0 1 4 1 2 2 2 no 0 0 0 0 2 0 0 0 0 0 2 2 0 175 70 511 650 127 Normal
472 57 M 24 1 1 1 36000 4 1 3 1 3 2 0 0 1 1 1 12 20 44 2 0 0 2 2 2 no 0 0 0 0 2 0 0 0 0 0 2 2 0 153 55 386 270 70 Obstruction
473 33 M 24 1 1 1 19000 7 1 2 1 3 2 0 0 1 1 1 16 10 16 2 0 0 2 2 2 yes 2 1 1 1 1 1 1 1 2 2 2 2 18 170 68 499 550 110 Normal
474 45 M 24 1 1 1 19000 7 1 2 2 3 2 0 0 2 2 2 20 22 15 2 0 0 2 2 2 no 0 0 0 0 2 0 0 0 0 0 2 2 11 160 53 438 470 107 Normal
475 54 M 24 1 2 2 3000 7 1 1 2 3 2 0 0 2 2 2 10 20 40 2 0 0 2 2 2 no 0 0 0 0 2 0 0 0 0 0 2 2 13 173 54 461 510 110 Normal
476 56 F 24 1 2 2 3000 7 1 1 2 4 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 no 0 0 0 0 1 3 1 1 2 2 2 1 18 138 45 264 220 83 Normal
477 35 F 24 1 2 2 3000 5 1 2 2 4 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 no 0 0 0 0 2 0 0 0 0 0 2 2 0 141 38 332 270 81 Normal
478 45 F 24 1 3 3 3000 5 1 1 2 4 1 2 2 2 3 0 0 0 0 2 0 0 2 2 2 no 0 0 0 0 2 0 0 0 0 0 2 2 0 133 33 280 290 103 Normal
479 48 F 24 1 3 3 3000 3 1 1 1 2 1 2 1 2 3 0 0 0 0 1 1 1 2 2 2 no 0 0 0 0 2 0 0 0 0 0 2 2 0 148 50 317 300 95 Normal
480 60 F 24 1 3 3 3000 3 1 1 1 1 1 3 1 1 3 0 0 0 0 1 1 1 2 2 2 no 0 0 0 0 2 0 0 0 0 0 2 2 0 147 39 280 160 57 Obstruction
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